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Neuregulin (Nrg) signaling plays an indispensable role in cardiac development and 
homeostasis. Since Nrg1β was shown to have beneficial effects on the heart in animal models 
of cardiac disease, several clinical trials are investigating its therapeutic value. The present 
study examines metabolic effects and molecular mechanisms that are induced by Nrg1β in 
cardiomyocytes, which could help to understand the positive effects observed in disease 
models in vivo and in clinics. 
 
Methods: 
Isolated neonatal rat ventricular myocytes (NRVMs), isolated adult rat ventricular myocytes 
(ARVMs), neonatal rats and adult mice served as models for our investigations. By 
pharmacological inhibition or siRNA knockdown, the role of proteins of interest was analyzed. 
For signaling analysis, proteins were extracted and Western blotting was performed. Glucose 
uptake was measured by [3H]-deoxy-D-glucose incorporation, glycolysis was investigated by 
Seahorse assay and protein synthesis was detected by [3H]-phenylalanine incorporation. 
GLUT4 translocation was evaluated by expressing a c-Myc-GLUT4-mCherry construct that was 
transfected into NRVMs. Proliferation of NRVMs was analyzed by immunofluorescence. In 
addition, neonatal rats and adult streptozotocin (STZ) mice were treated with Nrg1β or insulin 
to assess activation of glucose uptake pathways in the heart in vivo. 
 
Results: 
Similar to insulin and IGF-I, Nrg1β caused an 80% increase in glucose uptake and elevated the 
level of glycolysis in NRVMs. Dose-response curves of combinations of insulin and Nrg1β 
showed no additive effects on glucose uptake. Nrg1β activated the PI3K/Akt, the c-Src/FAK 
and the MAPK/Erk1/2 pathways, whereas only the PI3K/Akt and c-Src/FAK pathways 
appeared implicated in the glucose uptake. Pharmacological inhibition demonstrated that 
Nrg1β- and insulin-induced glucose uptake require PI3K and Akt. Both Nrg1β and insulin 
increased phosphorylation of Akt and AS160, whereas phosphorylation of IRS-1 at Tyr612 and 
IRS-1/2 degradation was only induced by insulin. Interestingly, Nrg1β and insulin showed an 
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additive effect on Akt phosphorylation, whereas this was not the case for Akt's target AS160. 
Knockdown of GLUT4 and an increase in GLUT4 translocation indicated its involvement in 
Nrg1β- and insulin-induced glucose uptake in NRVMs. Since glucose uptake is known to 
contribute to protein synthesis, we measured protein synthesis after Nrg1β stimulation, 
which was 50% increased, matching with elevated p70S6K1 and 4E-BP1 phosphorylation. 
Knockdown experiments revealed that the ErbB2/ErbB4 homodimer is required for the 
Nrg1β-induced glucose uptake as well as protein synthesis. Given the fact that glucose uptake 
and protein synthesis are part of proliferative responses, we analyzed proliferation of NRVMs 
in presence of Nrg1β. Interestingly, our preliminary data showed that Nrg1β increases 
proliferation of NRVMs, however only in combination with IGF-I. Furthermore, in order to 
compare our in vitro findings with an in vivo model, we analyzed the effect of Nrg1β on the 
neonatal rat heart. Western blot analysis of Nrg1β-stimulated neonatal hearts revealed 
comparable signaling effects as observed in vitro. In contrast to NRVMs and neonatal rat 
hearts, ARVMs did not increase the phosphorylation of Akt or AS160 and showed no effect 
on glucose uptake after Nrg1β stimulation. Moreover, while Nrg1β injection of diabetic STZ 
mice revealed a systemic effect on blood glucose clearance likely mediated by the liver, no 
activation of the PI3K/Akt/AS160 pathway was detectable in the hearts of these mice. 
 
Conclusions: 
Our major finding is that Nrg1β induces glucose uptake in NRVMs by a similar mechanism as 
insulin. This mechanism requires the ErbB2/ErbB4 homodimer, PI3K, Akt and AS160. 
Consistently, Nrg1β increases glucose uptake by GLUT4 translocation to a similar extent as 
insulin. Compared to insulin, Nrg1β signaling has distinct effects on IRS phosphorylation, 
which is not followed by IRS degradation. Altogether, our findings on glucose uptake, protein 
synthesis and proliferation contribute to a better understanding of the molecular 
mechanisms of Nrg1β in CMs, which may be applied to improve treatments of heart disease 






1.1. The heart and cardiomyocytes 
 
The heart acts as a pump and moves blood through the whole body. During evolution, the 
vertebral lineage gave rise to a closed circulation system, which consists of a cardiac muscle 
and a huge network of blood vessels. The vertebral heart needs to maintain a constant blood 
pressure by continuous contraction. In contrast to skeletal muscle, the heart is self-excitable, 
meaning that its contraction does not depend on an electrical stimulus from the nervous 
system, however the autonomous nervous system can influence heart activity. In the right 
atrium, the sinoatrial node generates electrical impulses, which spread into the wall of the 
heart and induce contraction of the cardiomyocytes (CMs). Contraction starts with the 
opening of voltage-gated sodium channels, which triggers the release of calcium ions from 
the sarcoplasmic reticulum through ryanodine receptors. This induces a conformational 
change of the sarcomeres, resulting in a shortening of the CMs. Shortly after contraction, 
calcium pumps bring the calcium back into the sarcoplasmic reticulum, consuming adenosine 
triphosphate (ATP). Since the whole process of excitation-contraction coupling needs a lot of 
energy, the heart has to be constantly supplied with nutrients and oxygen (Zipes et al., 2005). 
To meet this high demand of energy, the heart has a broad range of possible energy 
substrates. Besides glucose, lactate, ketones and amino acids, the main energy source of the 
adult heart are fatty acids (Bing, 1965; Lopaschuk and Jaswal, 2010; Neely et al., 1972). 
The mammalian heart consists of several cell types, mainly CMs, fibroblasts, smooth muscle 
cells, endothelial cells, Purkinje fibers and pacemaker cells (Xin et al., 2013). In the adult heart, 
the majority of CMs are post-mitotic cells, highly differentiated and have a low capacity to 
replicate. Fully differentiated CMs have a high number of thin invaginations of the 
sarcolemma, the so-called t-tubules, which facilitate ion exchange with the extracellular 
space (Fig. 1). The whole cytoplasm of CMs is filled with a network of sarcomeres, the 
indispensable unit for contraction. CMs are tightly linked with desmosomes and connected 
with gap junctions at the intercalated discs to be able to conduct the electrical current, which 
triggers contraction. Since performing rhythmic contractions requires a lot of energy, CMs 
have a high number of mitochondria (Walker and Spinale, 1999). Due to the fact that CMs are 
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highly differentiated cells, their ability to proliferate is very limited. In the human heart, it was 
observed that the turnover rate of CMs is only about 1% per year, which declines with higher 
age (Bergmann et al., 2009; Mollova et al., 2013). This low proliferation capacity of CMs is 
very likely a reason why the human heart undergoes scarring instead of replacement of 
cardiac tissue after injury. This is in contrast to other species like certain fishes, amphibians 
or reptiles, which are able to regenerate their heart after damage (Garbern et al., 2013; Yester 
and Kuhn, 2017). Excitingly, it was observed that even young mammals have the capacity to 
regenerate their heart (Porrello et al., 2011; Ye et al., 2018; Zhu et al., 2018). In the last years, 
many studies aimed to induce heart regeneration by activating CM proliferation (Leone et al., 
2015). One promising candidate in the field of heart regeneration is Neuregulin (Nrg) 
(Polizzotti et al., 2015). 
 
 




1.2. Neuregulin and ErbB receptors 
 
Nrg, which is also known as glial growth factor 1, Heregulin, Neu differentiation factor or 
acetylcholine receptor-inducing activity (ARIA), was first discovered in neural and cancer cells 
and belongs to the epidermal growth factor (EGF) family of growth factors (Falls et al., 1993; 
Holmes et al., 1992; Marchionni et al., 1993; Peles et al., 1992). So far, there are six neuregulin 
genes (NRG1-6) identified, of which NRG1 is the best characterized (Mei and Nave, 2014). 
NRG1 is widely expressed, namely in the brain, heart, breast, eye, skin, lung, gut, testis and 
skeletal muscle. NRG1 is a large gene (1’400 kb) on chromosome 8 in the human and mice 
genome and it encodes six types of proteins, which include more than 31 isoforms. The 
isoforms can be distinguished by their N-terminal region (I-VI), the EGF-like domain (,  or 
), and the juxtamembrane extracellular region (a, b, or c) (Falls, 2003). All isoforms have a 
variable cytoplasmic tail, a transmembrane domain and some isoforms include an 
immunoglobulin-like (Ig) domain (Parodi and Kuhn, 2014). The formation of most isoforms 
starts with a membrane-bound precursor. Upon activation by oxidative stress (Kuramochi et 
al., 2004a), the extracellular domain is cleaved off by A disintegrin and metalloproteinases 
(ADAM 10, ADAM17, ADAM 19) and gets released into the extracellular space (Fleck et al., 
2013; Horiuchi et al., 2005; Willem, 2016). Some Nrgs are cut intracellularly in the cytoplasmic 
tail and migrate to the nucleus for the promotion of gene expression (Bao et al., 2004). Nrgs 
mainly act paracrine/juxtacrine and bind to erythroblastic leukemia viral oncogene homolog 
(ErbB) receptor tyrosine kinases (Parodi and Kuhn, 2014). For our study, we used the 
extracellular domain or only the EGF domain of Nrg1β, the isoform which was demonstrated 
to be the most potent to bind and activate the ErbB receptors (Pinkas-Kramarski et al., 1996; 




Figure 2. Neuregulin1-4 and ErbB1-4 receptors (Guma et al., 2010) 
 
The ErbB receptor tyrosine kinases are closely related to the epidermal growth factor receptor 
(EGFR or ErbB1). There are three receptors involved in Nrg signaling, called ErbB2, ErbB3 and 
ErbB4, which are expressed in several organs including the heart (Parodi and Kuhn, 2014). At 
the N-terminus, the ErbB pro-receptor has a signal peptide that is necessary for correct 
localization to the plasma membrane. The mature receptor consists of an intracellular 
domain, a transmembrane domain and an extracellular domain (Fig. 2). The intracellular 
domain includes a juxtamembrane sub-domain, a phosphotyrosine kinase sub-domain and a 
non-catalytic C-terminal regulatory domain (Burgess et al., 2003). Each receptor has its own 
repertoire of ligands that can bind to its extracellular domain (Wilson et al., 2009). Upon 
ligand binding, the receptor undergoes a conformational change from a closed to an open 
conformation. In this open conformation, the receptor is able to dimerize and 
transphosphorylate tyrosine (Tyr) residues on the non-catalytic C-terminal regulatory 
domain. Except ErbB2, all receptors have a binding site for ligands. ErbB2 is constantly in the 
open conformation, but it needs to form a heterodimer with another ligand-bound ErbB 
receptor to become active (Cho et al., 2003). Besides receptor dimerization, the ErbB2 
receptor can also be activated in a different way. Cleavage of the extracellular receptor 
domain by a metalloprotease can lead to a constitutively active receptor, which may play a 
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role in certain breast cancers where ErbB2 is overexpressed. (Codony-Servat et al., 1999). 
ErbB3 has no functional catalytic domain, meaning it is able to bind ligands but cannot create 
a downstream signal. Like ErbB2, ErbB3 needs to form a heterodimer to transmit the signal 
(Citri et al., 2003). Only ErbB4 can form a fully functional homodimer. Upon receptor 
activation, the C-terminal domain is phosphorylated at Tyr residues, which serve as docking 
platform for intracellular signaling proteins with Src homology 2 (SH2) or phosphotyrosine-
binding (PTB) domains. Depending on the combination of receptors, different signaling 
pathways are activated (Burgess et al., 2003; Fuller et al., 2008). 
 
1.2.1. ErbB signaling 
 
Binding of Nrg to the ErbB3 or ErbB4 receptors and subsequent dimerization with the ErbB2, 
ErbB3 or ErbB4 activates the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt), the 
mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinases 1/2 (Erk1/2) 
and the proto-oncogene tyrosine-protein kinase Src (c-Src)/Focal adhesion kinase (FAK) 
pathway, which influence cellular processes like proliferation, migration, differentiation and 
survival (Fig. 3) (Pentassuglia and Sawyer, 2009). 
 
 
    Figure 3. The ErbB receptors activate several signaling pathways 
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The PI3K/Akt pathway is a well-studied signaling pathway known to be involved in the 
regulation of many cellular processes like protein synthesis, apoptosis or glucose uptake 
(Hemmings and Restuccia, 2012). In case of insulin-induced glucose uptake, insulin binding to 
its receptor activates PI3K via insulin receptor substrate-1 (IRS-1) and/or IRS-2 and produces 
the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 is necessary for 
the activation of 3-phosphoinositide-dependent protein kinase-1 (PDK1), which finally 
phosphorylates Akt at threonine (Thr)308. To fully activate Akt, the mammalian target of 
rapamycin complex 2 (mTORC2) needs to phosphorylate serine (Ser)473. Akt then 
phosphorylates Tuberous Sclerosis Complex 2 (TSC2) and proline-rich Akt substrate of 40 kDa 
(PRAS40), which leads to mTORC1 activation. mTOR phosphorylates then eukaryotic 
translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and ribosomal protein S6 
kinase beta-1 (p70S6K1). 4E-BP1 and p70S6K1 are involved in the regulation of protein 
synthesis. Subsequent to phosphorylation by mTOR, 4E-BP1 is inhibited and releases eIF4E, a 
translation initiation factor. p70S6K1 has a key role in regulation of cell growth and 
proliferation and it is activated by mTOR phosphorylation. Prolonged activation of PI3K, 
mTORC1 and p70S6K1 induces a negative feedback by phosphorylating IRS-1, which may 




 Figure 4. PI3K/Akt signaling pathway 
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Another pathway that is activated by Nrg is the MAPK/Erk1/2 pathway. The MAPK/Erk1/2 
pathway is mainly induced by the stimulation of growth factors. Other intensively studied 
MAPK pathways are the p38 and the c-Jun N-terminal kinases (JNK) pathways, which are 
primarily activated by a variety of stimuli related to stress like cytokines or DNA damage 
(Pearson et al., 2001). All MAPK pathways share some common features. They are composed 
of three kinases that phosphorylate themselves in a sequential manner: a MAPK, a MAPK 
kinase (MAPKK) and a MAPK kinase kinase (MAPKKK). Triggered by an interaction with a 
protein of the Rat sarcoma (Ras)/Ras homologue (Rho) family, the MAPKKK phosphorylate 
and activate a MAPKK, which then itself phosphorylates the MAPK. The activated MAPK, for 
example Erk1/2, is a Ser/Thr kinase that phosphorylates different substrates like transcription 
factors or several protein kinases named MAPK-activated protein kinases (MK) that regulate 
many biological functions. The MAPK/Erk1/2 pathway has been demonstrated to be a key 
regulator of cell proliferation and thus, some anticancer drugs are targeting this pathway 
(Roux and Blenis, 2004). 
The c-Src/FAK pathway is as well activated by Nrg stimulation (Kuramochi et al., 2006). c-Src 
and FAK are non-receptor protein tyrosine kinases involved in cytoskeleton regulation, 
survival and proteins synthesis (Thomas and Brugge, 1997). c-Src belongs to the Src family of 
protein tyrosine kinases, which can interact with a broad spectrum of cellular receptors and 
other targets. FAK is part of the focal adhesion complex that links the cytosol with the 
extracellular matrix via integrins (Graham et al., 2015). Nrg1β was demonstrated to trigger 
phosphorylation of c-Src at Tyr416 and Tyr215, two known kinase-activating sites of c-Src, and 
FAK at Tyr861 in adult CMs (Kuramochi et al., 2006). Moreover, Kuramochi et al. concluded 
that c-Src/FAK signaling contributes to cytoskeletal remodeling and thereby enables isolated 
adult rat ventricular myocytes (ARVMs) to form cell-to-cell contacts. 
Since many signaling molecules of these pathways have been shown to be implicated in 
different kind of cancer types, drugs against several targets have been developed. To analyze 




1.2.2. Neuregulin in the heart 
 
Since more than 20 years, it is known that Nrg and its receptors (ErbB2-4) are indispensable 
for proper heart development and homeostasis (Odiete et al., 2012). Besides the important 
role of the Nrg/ErbB signaling in the heart, it is also fundamental for the nervous system 
regulating myelination, synaptic plasticity, neural circuitry and neurotransmission (Mei and 
Nave, 2014). Even more, it was shown that Nrg1, ErbB2 and ErbB4 are involved in early 
embryogenesis (Fig. 5). The knockout of each gene is embryonically lethal because of severe 
problems with heart formation, namely impaired ventricular trabeculation, and thus the 
animals die due to heart failure (Gassmann et al., 1995; Lee et al., 1995; Meyer and 
Birchmeier, 1995). Embryos that are lacking ErbB3 have defects in the endocardial cushion 
formation, which as well results in embryonic lethality (Erickson et al., 1997). Recently, Nrg1 
was demonstrated to promote synthesis of myocardial extracellular matrix, which is 
necessary for proper formation of the trabeculae (Del Monte-Nieto et al., 2018). Interestingly, 
Rentschler et al. observed that Nrg1 contributes also to the development of the heart 
conduction system (Rentschler et al., 2002). In addition, Rentschler et al. showed that Nrg1 
triggered differentiation of embryonic CMs into cells of the cardiac conduction system and 
fetal CMs into cardiac pacemaker-like cells. 
 
 
     Figure 5. The roles of Nrg/ErbB in heart development (Odiete et al., 2014) 
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In contrast to earlier publications, which detected only ErbB1/EGFR, ErbB2 and ErbB4 in the 
adult heart, recently it was demonstrated that all four ErbB receptors are expressed 
(Camprecios et al., 2011). They showed that the expression of ErbB2 and ErbB4 decreases 
within the first week after birth, whereas ErbB3 expression increases and remains high at later 
time points. Conditional cardiomyocyte-specific disruption of ErbB2 or ErbB4 leads to dilated 
cardiomyopathy. Moreover, cancer treatment, where chemotherapy is combined with a 
recombinant monoclonal antibody against ErbB2 (Trastuzumab), may result in cardiac 
dysfunction (Crone, 2002; Garcia-Rivello et al., 2005; Ozcelik et al., 2002; Slamon et al., 2001). 
This demonstrates that ErbB/Nrg signaling is necessary to keep homeostasis of the adult 
heart. In addition, Nrg is important for the heart during stress situations. It was observed that 
Nrg expression is increased upon mechanical strain (Lemmens et al., 2006) and during 
pregnancy, a time when cardiac demand is elevated (Lemmens et al., 2011). Lemmens et al. 
showed that when pregnant mice were treated with Lapatinib, a dual ErbB1/ErbB2 tyrosine 
kinase inhibitor, cardiac function was reduced and about 25% of the pregnant animals died 
prematurely. 
In the heart, Nrg is released by the microvascular endothelium and binds the ErbB receptors 
on CMs (Cote et al., 2005). It was observed that Nrg1 has an anti-apoptotic effect on neonatal 
and adult CMs cultured in serum-free medium (Zhao et al., 1998). In addition, Baliga et al. 
demonstrated that the recombinant human glial growth factor (rhGGF-2), a soluble Nrg1 
peptide, induces hypertrophy in NRVMs (Baliga et al., 1999). Nrg1β protects CMs from β1-
adrenergic receptor–induced cell death and has a negative inotropic effect in isolated 
papillary muscles (Kuramochi et al., 2004b; Lemmens et al., 2004). Furthermore, it was shown 
that Nrg1 has anti-fibrotic and anti-remodeling effects in a swine model of heart failure 
(Galindo et al., 2014). Moreover, several studies claim that Nrg1 enhances proliferation of 
CMs in vitro and in vivo (Bersell et al., 2009; D'Uva et al., 2015; Gemberling et al., 2015; Ma 
et al., 2016; Polizzotti et al., 2015; Zhao et al., 1998). Recently, our group demonstrated that 
Nrg1β is as potent as insulin to induce glucose uptake in neonatal CMs by a mechanism that 
implicates PI3K, Akt and Akt substrate of 160 kDa (AS160, also known as TBC1D4) 
(Pentassuglia et al., 2016). Previously, Canto et al. observed that Nrg1β increased glucose 
uptake as well in L6E6 skeletal muscle cells, but independently of Akt (Canto et al., 2004). 
These data show that the Nrg1β-induced signaling mechanism leading to increased glucose 
uptake differs between CMs and skeletal muscle cells. 
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1.3. Glucose metabolism 
 
For many organisms, glucose is a very important source of energy. Glucose is catabolically 
processed during glycolysis to pyruvate or besides its intermediates, serves as substrate for 
several anabolic pathways. Rapidly after glucose uptake, glucose gets phosphorylated by 
hexokinase turning into glucose-6-phosphate, which is hydrophilic and therefore is retained 
in the cell. Glucose-6-phosphate can either be stored as glycogen during glycogen synthesis, 
enter the pentose phosphate pathway and the polyol pathway, or it gets degraded by 
glycolysis. During glycolysis, glucose-6-phosphate turns into fructose-6-phosphate, which can 
enter the hexosamine biosynthetic pathway that delivers substrates for glycosylation of 
proteins or it can be further degraded. When fructose-6-phosphate is further degraded by 
glycolysis, after several enzymatic steps, pyruvate is produced. Finally, pyruvate can be turned 
into acetyl-CoA and enter the tricarboxylic acid (TCA) cycle for ATP production in the 
mitochondria or it can be turned into lactate, which might be secreted by the cell (Shao and 
Tian, 2015). 
 
1.3.1. The role of insulin and IGF-I in glucose metabolism 
 
Insulin is a hormone that regulates blood glucose levels and influences anabolic effects like 
protein, fatty acid and carbohydrate synthesis. Its major effects on glucose metabolism are 
stimulation of glucose uptake and glycolysis in muscle and adipose tissue, activation of 
glycogen synthesis in several tissues and inhibition of glycogenolysis and gluconeogenesis in 
the liver (Dimitriadis et al., 2011). In comparison to insulin, the insulin-like growth factor (IGF-
I) has similar effects on glucose handling but its mitogenic potential is much higher (Beguinot 
et al., 1985). IGF-I is structurally related with proinsulin and shares 48% of the amino acid 
sequence. At physiologic concentrations, Insulin binds the insulin receptor (InsR) and IGF-I 
binds the IGF-I receptor (IGF-IR). Interestingly, IGF-I seems to enhance insulin sensitivity, very 
likely by an indirect mechanism and at higher concentrations, IGF-I can also bind the InsR 
(Clemmons, 2006). In addition, the InsR and IGF-IR have a very similar structure and can form 
hybrid heterodimers, thereby activating both receptor substrates. The two receptors have a 
common substrate, namely IRS (Chang et al., 2004; Clemmons, 2006). 
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1.3.2. IRS proteins 
 
There are four IRS isoforms in human, namely IRS-1, IRS-2, IRS-3 and IRS-4. IRS-1 and IRS-2 
are involved in the regulation of glucose uptake and they are part of the classical insulin-
induced signaling cascade. Both are activated by the InsR and the IGF-IR and serve as 
scaffolding proteins to attract downstream effector proteins. Upon activation of the 
receptors, the PI3K pathway is strongly induced. IRS proteins are mainly regulated by 
ubiquitin-mediated degradation and phosphorylation at Tyr, Ser and Thr residues. The 
available phosphorylation sites on IRS are very numerous and their effect on IRS activity is 
difficult to elucidate. A negative feedback loop via mTOR/S6K1 has been associated with 
increased phosphorylation on Ser307 (rat) or Ser312 (human) respectively, which leads to its 
inactivation (Copps and White, 2012; Greene et al., 2003; Harrington et al., 2005). On the 
other hand, Tyr612 and Tyr632 have been shown to be required for insulin-induced PI3K 
activation and glucose transporter 4 (GLUT4) translocation (Esposito et al., 2001). In the heart 
and other organs, IRS-1 and IRS-2 are thought to contribute to the development of insulin 
resistance in type 2 diabetes mellitus (T2DM) (Lavin et al., 2016). Showing the importance of 
IRS for the heart, myocardium-specific double knockout mice of IRS-1 and IRS-2 die due to 
heart failure within 6-8 weeks after birth (Qi et al., 2013). 
 
1.3.3. Cardiac glucose metabolism 
 
The healthy adult heart consumes primarily fatty acids and only to a minor part glucose. Once 
glucose enters a cell, it is immediately phosphorylated and eventually stored as glycogen. In 
contrast to the fetal and neonatal heart, the adult heart has only little glycogen storage (about 
30% vs. 2%). The level of glycogen can be increased by hyperinsulinemia, fasting or elevated 
levels of fatty acids in the blood (Depre et al., 1999). Under stress conditions like ischemia or 
cardiac hypertrophy, the adult heart increases the consumption of glucose at the expense of 
fatty acids to sustain the high energy demand needed for continuous contraction (Szablewski, 
2017). This is associated with a changed pattern of gene expression, resembling that of the 
fetal and neonatal heart (Razeghi et al., 2001). In contrast to the adult heart, the fetal and 
neonatal heart rely mainly on glycolysis as energy source, which correlates with higher 
proliferation capacity. Soon after birth, the heart undergoes a metabolic switch, increasing 
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oxidative phosphorylation and reducing glycolysis (Lopaschuk and Jaswal, 2010). This 
metabolic switch likely occurs because there is suddenly more oxygen available and in 
addition, many species feed their offspring with milk, which is rich in fat (Onay-Besikci, 2006). 
 
1.3.4. Glucose transporters in the heart 
 
Since glucose cannot cross the plasma membrane, the cells have glucose transporters that 
allow facilitative diffusion of hydrophilic sugar molecules. In the process of glucose uptake 
several glucose transporters are involved, namely the GLUT, SGLT (Sodium-glucose linked 
transporters) and SWEET proteins. The predominant transporters in the heart are GLUT1 and 
GLUT4, whereas GLUT3, GLUT8, GLUT10, GLUT12 and SGLT1 were detected as well (Aerni-
Flessner et al., 2012; Szablewski, 2017). 
GLUT1 is encoded by the SLC2A1 gene and the protein consists of 492 amino acid residues 
that form 12 transmembrane segments located in the plasma membrane. GLUT1 mainly 
mediates passive diffusion transport of glucose, but also mannose, galactose, glucosamine 
and reduced vitamin C are physiological substrates. GLUT1 can be inhibited by Cytochalasin 
B, which binds to the sugar-binding site (Carruthers and Helgerson, 1991). It was shown that 
GLUT1 is indispensable for proper development, since GLUT1 knockout mice are 
embryonically lethal (Heilig et al., 2003). In general, GLUT1 is ubiquitously expressed, whereas 
in the heart, GLUT1 is mainly expressed during development (Mueckler and Thorens, 2013; 
Shao and Tian, 2015). 
GLUT4 is implicated in insulin-stimulated glucose uptake. GLUT4 is structurally very similar to 
GLUT1, however GLUT4 has a higher affinity for glucose (Km ≈ 4–7 mM vs. Km ≈ 20–26 mM) 
(Nishimura et al., 1993; Palfreyman et al., 1992). It is highly expressed in insulin-sensitive 
tissues like skeletal muscle, adipose tissue and the heart. GLUT4 dominates in adult CMs and 
is primarily found in intracellular vesicles. Upon increased levels of insulin or muscle 
contraction, GLUT4 vesicles translocate to the plasma membrane and facilitate glucose 
uptake. A defect of this translocation mechanism paralleled with increased insulin secretion 
is referred to insulin resistance, leading to T2DM (Mueckler and Thorens, 2013; Shao and Tian, 
2015). GLUT4 can be inhibited by human immunodeficiency virus (HIV) protease inhibitors, 
for example Indinavir (Hresko and Hruz, 2011). 
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1.3.5. Glucose uptake by GLUT4 
 
Upon insulin stimulation, the InsR is autophosphorylated and turns on its tyrosine kinase 
activity. The active InsR phosphorylates IRS proteins, which recruit PI3K through the p85 
regulatory subunit that triggers activation of the catalytic subunit p110. PI3K induces the 
formation of PIP3 from phosphatidylinositol (4,5)-bisphosphate (PIP2) that serves as docking 
platform for Akt. Once Akt has bound it gets phosphorylated at Thr308 by PDK1. Active Akt 
leads to increased phosphorylation of AS160 at Thr642 amongst other sites, which inhibits 
AS160 activity. AS160 is a Rab (Ras-related in brain) guanine triphosphatase (GTPase)-
activating protein that inhibits Rab-GTP by converting guanine triphosphate (GTP) to guanine 
diphosphate (GDP). When AS160 is phosphorylated by Akt, its inhibitory effect is blocked and 
Rab-GTP can trigger the translocation of GLUT4 storage vesicles (GSV) and fusion with the 
plasma membrane, enabling glucose uptake (Fig. 6) (Rowland et al., 2011). 
 
 
        Figure 6. Process of GLUT4 translocation (James D. E., 2005) 
 
1.4. Neuregulin and glucose metabolism 
 
Nrg signaling was shown to play a role in metabolic regulation in skeletal muscle and the liver 
(Guma et al., 2010). Nrg induces glucose uptake in skeletal muscle cells by triggering 
translocation of glucose transporters, namely GLUT1, GLUT3 and GLUT4 (Suarez et al., 2001). 
In 2004, Canto et. al demonstrated that Nrg induces GLUT4 translocation in skeletal muscle 
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cells in an additive manner to insulin, proposing different regulatory mechanisms of these 
two stimuli (Canto et al., 2004). In addition, Nrg is also involved in contraction-induced 
glucose uptake in skeletal muscle. This was demonstrated by blocking the ErbB4 receptor 
after a caffeine-induced cytosolic calcium (Ca2+) increase, which resulted in reduced glucose 
uptake. The proposed mechanism involves the interaction of protein kinase ζ (PKCζ) with 
calmodulin-dependent protein kinase II (CAMKII) triggering GLUT4 translocation (Canto et al., 
2006). Furthermore, exposure of skeletal muscle cells to low Nrg concentrations over a long 
period of time stimulated mitochondrial biogenesis and increased GLUT4 levels (Canto et al., 
2007). In contrast, chronic exposure of skeletal muscle cells to Nrg resulted in reduced GLUT4 
expression and elevated levels of GLUT1 and GLUT3 (Suarez et al., 2001). Like in skeletal 
muscle, Nrg also influences glucose consumption of the liver. In diabetic rats and mice, Nrg1 
recently was shown to improve the response to the glucose tolerance test (Ennequin et al., 
2015; Lopez-Soldado et al., 2016). 
 
1.5. Clinical relevance of Neuregulin1 
 
Worldwide, the number of people suffering from cardio vascular diseases increased 
tremendously during the last century (Cooper et al., 2000; Sanchis-Gomar et al., 2016). 
Prolonged lifetime and changes in lifestyle are the main factors that contribute to this 
observation. Not only in the Western world, but also in the Third world, more and more 
people nourish from a high-caloric diet and do not practice enough sports anymore, which 
favors the development of heart disease. Especially in Western countries, this is a severe 
problem, which causes increasing health costs every year. At the same time, medicine has 
found ways to prevent the development of heart disease, which is reflected by a decrease in 
morbidity due to heart failure in the last 50 years. However, the World Health Organization 
published that cardiovascular diseases remains the leading cause of death worldwide 
(www.who.int). 
A big issue is the limited capacity of the human heart to recover after an injury. In contrast to 
other species, the human heart cannot replace the damaged cardiac muscle tissue but 
undergoes scarring. Unfortunately, after the formation of a scar the heart shows reduced 
contractility, which results in impaired cardiac function (Weber et al., 2013). The prevention 
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of scarring and the improvement of cardiac function of the stressed heart is an ongoing field 
of research. People state, that under stress conditions like pathological hypertrophy or 
ischemia the diseased heart changes its energy substrate from fatty acids to an increased 
consumption of glucose, resembling the energy profile of a heart during development (Allard, 
2004; Opie, 1990; Taegtmeyer et al., 2010). 
There are two kinds of cardiac hypertrophies, physiological and pathophysiological 
hypertrophy. Physiological hypertrophy is an adaptation of the healthy heart due to repetitive 
exercise and pathological hypertrophy is triggered by heart disease that alter upstream 
stimuli and signaling mechanisms, which are harmful to the heart and may finally lead to heart 
failure (Nakamura and Sadoshima, 2018). It was observed that the metabolic profile of both 
types of cardiac hypertrophies are distinct (Strom et al., 2005). Whereas physiologic cardiac 
hypertrophy is related to increase β-oxidation of fatty acids, during pathologic cardiac 
hypertrophy glucose metabolism is increased. As previously mentioned, the healthy adult 
heart relies mainly on fatty acids and only to a minor part on glucose (Bing, 1965). 
Interestingly, NRG1 was shown to be upregulated after endurance exercise that leads to 
physiologic cardiac hypertrophy (Waring et al., 2014). Previously, Nrg1β has been 
demonstrated to induce hypertrophy in neonatal CMs (Baliga et al., 1999). Moreover, 
reduced levels of ErbB2 and ErbB4 were associated with the transition from compensatory 
hypertrophy to heart failure (Rohrbach et al., 1999). Very likely, Nrg1β plays a role in both 
types of hypertrophic responses of the heart, however further studies are required. 
Also during an ischemic period, the heart adapts its energy substrate to increased glucose and 
reduced fatty acids consumption due to the lack of oxygen necessary for oxidative 
phosphorylation (Stanley et al., 2005). After an ischemic insult, ErbB3 was demonstrated to 
contribute to the recovery of the heart (Morano et al., 2017) and it was observed that the 
myocardial endothelium releases Nrg1 during ischemia-reperfusion (Kuramochi et al., 2004a). 
In addition, it was shown that administration of Nrg1β to swine with heart failure after 
myocardial infarction has beneficial effects on cardiac function (Galindo et al., 2014). 
Changes in the metabolic profile of the heart were as well observed in T2DM. Well known 
features of T2DM are hyperglycemia, hyperinsulinemia, increased levels of fatty acids, 
elevated levels of inflammatory cytokines and changes in molecular pathways in CMs 
triggered by high-fat diet, inactivity and increased body weight (Bugger and Abel, 2014; 
Fonseca, 2009; Kota et al., 2011). Patients with T2DM may develop diabetic cardiomyopathy 
 20 
(DCM), also known as lipotoxic cardiomyopathy, which is characterized by diastolic 
dysfunction due to reduced glucose metabolism and increased fatty acids consumption that 
leads to intramyocardial lipid accumulation (Miki et al., 2013; Szczepaniak et al., 2007). In the 
diabetic heart, the CMs are deprived of glucose and limited to fatty acids as energy source.  
These factors lead to impaired cardiac contractility, myocytes dysfunction and cell death. 
Recently, it was shown that intraperitoneal (i.p.) injections of Nrg1β enhances systemic 
glucose uptake in mice (Ennequin et al., 2015) and Nrg1β was observed to increase glucose 
uptake in skeletal muscle (Canto et al., 2004). Moreover, Nrg1β reduced CMs stiffening 
caused by insulin-dependent titin modifications in T2DM (Hopf et al., 2018). Interestingly, in 
a rat streptozotocin (STZ) model for diabetic cardiomyopathy, reduced phosphorylation of 
ErbB2 and ErbB4 was detected, indicating impaired Nrg signaling (Gui et al., 2012). 
In the last years, several clinical studies were performed, showing that Nrg1β is a promising 
drug candidate for the treatment of chronic heart failure (Gao et al., 2010; Jabbour et al., 
2011b; Lenihan et al., 2016). However, the molecular mechanisms behind these positive 




2. Aims of the thesis 
 
Nrg1β is known to be very important for heart development and it was shown to have 
beneficial effects on the stressed heart in vivo and in clinical trials. However, concrete 
molecular mechanisms in CMs that are related to these beneficial effects induced by Nrg1β 
are scarcely known so far. Therefore, we were interested in mechanisms that are induced by 
Nrg1β in NRVMs, specifically glucose uptake, which may lead to a better performance of the 
heart under stress conditions. Our findings might contribute to improve the treatment of 
heart disease, using Nrg1β as drug to ameliorate heart function. The specific aims of our 
studies were to: 
 
1. examine the effect of Nrg1β on glucose uptake, glycolysis and protein synthesis in 
NRVMs. We assess glucose uptake after Nrg1β stimulation by [3H]-deoxy-D-glucose 
incorporation, estimate the rate of glycolysis with the glycolytic stress test from 
Seahorse and measure protein synthesis by [3H]-phenylalanine incorporation. 
Moreover, we analyze the signaling pathways and proteins that are involved in Nrg1β 
stimulation in NRVMs, focusing on glucose uptake-related signaling and the mTOR 
pathway and compare the effects of Nrg1β stimulation with insulin and IGF-I. 
 
2. elucidate the molecular mechanism whereby Nrg1β triggers glucose uptake in NRVMs. 
We analyze the contribution of GLUT1 and GLUT4 with an siRNA approach and detect 
GLUT4 translocation after Nrg1β and insulin stimulation by immunofluorescence. 
 
3. investigate the effect of Nrg1β in vivo, using neonatal rats and STZ mice as models. 
We treat the animals with Nrg1β and insulin and analyze glucose uptake-related 
signaling effects in the heart. 
 
4. clarify if Nrg1β influences glucose uptake as well in isolated ARVMs. We assess glucose 





3.1. Neuregulin-1 promotes glucose uptake via PI3K/Akt in neonatal rat 
cardiomyocytes 
 





































































































3.1.2. Supplementary data (unpublished results) 
 
The data presented here were not included in our publication, although the experiments were 
part of my PhD project. Some results did not reach significance due to limited repetitions of 
the experiments, whereas other experiments had a negative outcome. Nevertheless, as my 
preliminary data may lead to interesting future studies, I would like here to present some of 
them. The aims of the experiments were: 
(1) to examine the role of c-Src and FAK in Nrg1β-induced glucose uptake by siRNA 
knockdown. 
(2) to investigate the contribution of ErbB2 and ErbB4 to protein synthesis using siRNA 
knockdown. 
 
c-Src and FAK may contribute to Nrg1β-induced glucose uptake 
 
c-Src and FAK are involved in cytoskeleton regulation, survival and proteins synthesis (Thomas 
and Brugge, 1997). c-Src can interact with a broad spectrum of cellular receptors and other 
targets like FAK, which is part of the focal adhesion complex that links the cytosol with the 
extracellular matrix via integrins (Graham et al., 2015). Previously, FAK was demonstrated to 
interact and increase PI3K activity (Chen and Guan, 1994). Furthermore, Nrg1β in known to 
trigger phosphorylation of c-Src at Tyr416 and Tyr215 and FAK at Tyr861 in adult CMs (Kuramochi 
et al., 2006). Therefore, we investigated a possible link between c-Src/FAK and Nrg1β -
induced glucose uptake signaling. 
We found that Nrg1β-stimulated glucose uptake was blocked after pharmaceutical inhibition 
of c-Src with Dasatinib or PP2 (Pentassuglia et al., 2016). Since these inhibitors may have some 
off-target effects, we also used a non-pharmacological approach to further prove the 
involvement of FAK and c-Src. Knockdown of c-Src and FAK in NRVMs with specific siRNAs 
partially reduced basal glucose uptake, but the Nrg1β-stimulated glucose uptake was not 
affected (Fig. 1). The knockdown was not complete, which can be seen on the Western blots 
of c-Src and FAK. Therefore, while not providing any proof, these results also do not exclude 
a contribution of c-Src and FAK to the Nrg1β-induced glucose uptake. Further studies are 








Figure 1. Glucose uptake after siRNA knockdown of c-Src and FAK 
A: NRVMs were transfected with siRNAs specific for c-Src. 48 h after transfection, NRVMs 
were stimulated for 30 min with Nrg1β (10 ng/ml) or control vehicle. Glucose uptake was 
assessed by 30 min incubation with 1 μCi/ml [3H]-deoxy-D-glucose. Counts were normalized 
to total protein/well. siRNA-transfected NRVMs were treated for 30 min with Nrg1β (10 
ng/ml). Western blot analysis was performed to detect c-Src (representative experiment, 
mean +/- standard deviation, STDV). B: NRVMs were transfected with siRNAs specific for FAK 
and treated in the same way as above (representative experiment, mean +/- STDV). *P < 0.05, 




ErbB2 and ErbB4 are required for Nrg1β-induced protein synthesis 
 
Protein synthesis plays an important role in physiological as well as pathological cardiac 
hypertrophy (Nakamura and Sadoshima, 2018). Moreover, glucose uptake was demonstrated 
to be required for protein synthesis in CMs by regulating branched chain amino acid (BCAA) 
degradation (Shao et al., 2018). Nrg1β has been shown to increase protein synthesis in CMs 
(Baliga et al., 1999), but the responsible receptor has not been identified. Therefore, as first 
aim, we analyzed protein synthesis in NRVMs and tried to identify the responsible receptors 
necessary for Nrg1β-induced protein synthesis. We observed a complete inhibition of Nrg1β-
induced protein synthesis after treatment with the ErbB1/2 inhibitor Lapatinib (Pentassuglia 
et al., 2016). Since Western blot analysis showed that Lapatinib not only blocked 
phosphorylation of ErbB2 but also ErbB4, protein synthesis was measured after ErbB2 and 
ErbB4 knockdown by siRNA. Reduced protein levels of either receptor lowered the 
incorporation of [3H]-phenylalanine (Fig. 2A). The high efficiency of the knockdown was 
revealed by Western blot analysis (Fig. 2B). Due to variability between the three experiments, 
the effect of Nrg1β on protein synthesis did not reach significance (P=0.053) in the scrambled 
controls. However, in previous experiments with scrambled siRNA, Nrg1β significantly 
increased protein synthesis (Pentassuglia et al., 2016). Therefore, similar to what we found 
for the glucose uptake, both ErbB2 and ErbB4 seem to be involved in the Nrg1β-induced 
protein synthesis. In conclusion, these data show the involvement of the ErbB2/4 
heterodimer in Nrg1β-induced protein synthesis in NRVMs. 
As second aim, we wanted to test if Nrg1β-induced glucose uptake contributes to protein 
synthesis in NRVMs. Therefore, we blocked glucose uptake pharmacologically with a GLUT4 
inhibitor (Indinavir) or with siRNAs against GLUT1 or GLUT4. Indinavir reduced basal glucose 
uptake and protein synthesis but had no effect on the insulin- and Nrg1β-induced response 
(n = 3/1, data not shown). These data demonstrate that glucose uptake contributes to overall 
protein synthesis in NRVMs. Furthermore, it might indicate that next to GLUT4 one or more 
additional glucose transporters are involved in insulin- and Nrg1β-stimulated glucose uptake 
in NRVMs. Moreover, our preliminary data of the siRNA approach did not reveal any effect 
on protein synthesis. Hence, further experiments are required to elucidate the contribution 
of Nrg1β-induced glucose uptake to protein synthesis. In this context, one could analyze the 
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role of BCAA regulation, which links glucose uptake with protein synthesis as proposed by 






Figure 2. Protein synthesis after siRNA knockdown of ErbB2 and ErbB4 
A: NRVMs were transfected with siRNA specific for ErbB2 and ErbB4. 48 h after transfection, 
NRVMs were stimulated for 24 h with Nrg1β (10 ng/ml) or control vehicle in presence of 2 
μCi/ml [3H]-phenylalanine for protein synthesis measurement. Counts were normalized to 
total DNA/well (n=3, mean +/- STDV). B: siRNA-transfected NRVM protein extracts were 
analyzed by Western blot analysis to detect ErbB2 and ErbB4 (representative experiment). 
Control vehicle (C), Nrg1β (N), scrambled (Scr.). 
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Background/Aims: During stress conditions such as pressure overload and acute ischemia, 
the myocardial endothelium releases neuregulin (Nrg), which acts as cardioprotective factor 
and supports recovery of the heart. Recently, we demonstrated that Nrg1β enhances glucose 
uptake in neonatal rat ventricular myocytes (NRVMs) via PI3K and Akt. The present study 
aimed to elucidate the mechanism whereby Nrg1β activates glucose uptake in more detail in 
comparison to the well-studied insulin-induced glucose uptake. Methods: Isolated NRVMs 
and adult rat cardiomyocytes (CMs) were treated with Nrg1β or insulin for comparison. Prior 
to stimulation, proteins of interest were knocked down using siRNAs. Glucose uptake was 
measured by 3H-deoxy-D-glucose incorporation, glycolysis by Seahorse and proteins by 
Western blot. To detect GLUT4 translocation, a c-Myc-GLUT4-mCherry construct was 
transfected using AMAXA Nucleofector and detected by immunofluorescence. Neonatal rats 
were treated with Nrg1β or insulin to assess activation of glucose uptake pathways in the 
intact heart. Results: Combinations of Nrg1β with increasing doses of insulin did not yield any 
additive effect on glucose uptake, indicating that the mechanisms of both stimuli are very 
similar. In c-Myc-GLUT4-mCherry transfected NRVMs, we demonstrate that Nrg1β increases 
sarcolemmal GLUT4 by 16-fold, similar to insulin. In contrast to insulin, IRS-1 is not 
phosphorylated at Tyr612 in presence of Nrg1β, indicating that IRS-1 is not implicated in signal 
transmission. Treatment of neonatal rats with Nrg1β showed a signaling response 
comparable with our in vitro findings, including increased phosphorylation of ErbB4 at Tyr1284, 
Akt at Thr308 and Erk1/2 at Thr202/Tyr204. In contrast, in adult rat CMs Nrg1β only increased 
Erk1/2 phosphorylation without having any effect on AS160 and glucose uptake, indicating 
that Nrg1β signaling and function in NRVMs differs from that in adult rat CMs. Conclusions: 
Our results show that similar to insulin, Nrg1β induces glucose uptake in NRVMs by activating 
the PI3K pathway and GLUT4 translocation. Unlike insulin, the Nrg-induced effect is not 




Since more than 20 years it is known that neuregulin1 (Nrg1) and its receptors called ErbB2, 
ErbB3 and ErbB4, are indispensable for proper cardiac development and homeostasis 
(Erickson et al., 1997; Gassmann et al., 1995; Lee et al., 1995; Meyer and Birchmeier, 1995). 
More recently, Nrg1 also gathered a lot of attention in the field of cardiac regeneration. In 
zebrafish and mouse models, Nrg1 was demonstrated to contribute to regeneration of the 
heart by inducing cardiomyocyte proliferation (Harvey et al., 2015; Yester and Kuhn, 2017). 
In addition, clinical trials are investigating the therapeutic value of Nrg1 and published data 
show its positive effects on cardiac function in patients with heart disease (Gao et al., 2010; 
Jabbour et al., 2011b; Lenihan et al., 2016). However, the cellular and molecular mechanisms 
responsible for these beneficial effects are poorly understood. 
Nrg1/ErbB induces the PI3K, MAPK/Erk1/2 and Src/FAK pathways, which regulate several 
cellular functions including cytoskeletal organization, cell growth and survival, and 
angiogenesis (Pentassuglia and Sawyer, 2009). Only ErbB3 and ErbB4 can bind ligands, 
whereas ErbB2 is an orphan receptor (Fuller et al., 2008). Nrg1/ErbB signaling activation 
requires the formation of ErbB homo- or heterodimers. Recently, we demonstrated that 
Nrg1β enhances glucose uptake in NRVMs by a mechanism that implicates the ErbB2/ErbB4 
heterodimer, PI3K and Akt (Pentassuglia et al., 2016). Similar to skeletal muscle and fat cells, 
glucose uptake by cardiac cells is thought to be mediated by glucose transporters (GLUT). The 
fetal heart mainly expresses GLUT1, whereas in the adult heart GLUT4 dominates (Riehle and 
Abel, 2016; Shao and Tian, 2015). This pattern of GLUT expression matches the well-studied 
energy substrate profile of the fetal vs. the adult heart, which primarily consume glucose vs. 
fatty acids, respectively (Lopaschuk and Jaswal, 2010). Under conditions of stress such as 
ischemia or pressure overload, the adult heart increases glucose uptake and reduces fatty 
acid consumption to sustain the high energy demand needed for continuous contraction 
(Riehle and Abel, 2016; Shao and Tian, 2015; Szablewski, 2017). Under such stress conditions, 
the myocardial endothelium also releases Nrg1 as cardioprotective factor (Hedhli et al., 2011; 
Kuramochi et al., 2004a). Our previously published finding that Nrg1 stimulates glucose 
uptake in NRVMs points to glucose uptake as one of the basic mechanisms underlying its 
cardioprotective properties. Given the important therapeutic potential of Nrg1, our present 
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study aimed to better understand the mechanisms whereby Nrg1 enhances glucose uptake 
in NRVMs, and to extend the findings to adult CM and in vivo models. The classical insulin-
stimulated glucose uptake involves a cascade of enzymatic reactions comprising 
phosphorylation of the InsR, IRS, PI3K, PIP3, PDK1, Akt, AS160 and Rab, which finally triggers 
GLUT4 vesicles to translocate and fuse with the plasma membrane (Jaldin-Fincati et al., 2017; 
Leto and Saltiel, 2012). Our present study analyzes the mechanism of Nrg1β-stimulated 
glucose uptake in comparison to that induced by insulin. Moreover, we compare neonatal 
with adult rat CMs and evaluate the responses to Nrg1β using a neonatal in vivo model. 
 
Materials and Methods 
 
Isolation and transfection of primary cardiomyocytes 
Neonatal rat ventricular myocytes (NRVMs) were isolated from 1- to 2-days-old rats. The hearts were 
predigested in 0.05% trypsin–EDTA (Gibco) over-night, followed by serial digestions in 0.09% 
collagenase type II (Worthington). To reduce the number of cardiac fibroblasts, cells were pre-plated 
twice in T75 culture flasks (Sarstedt). NRVMs were seeded on plastic culture dishes (BD Falcon) or 
transfected with siRNA (Dharmacon: scrambled, ErbB3, ErbB4, GLUT1 and GLUT4) or a plasmid 
(Addgene: 64049) according to Amaxa's Neonatal Rat Cardiomyocyte Nucleofector kit (VPE-1002) and 
kept at 37°C and 5% CO2 in Dulbecco's modified Eagle's medium (DMEM; Gibco) supplemented with 
10% heat-inactivated fetal calf serum, penicillin (100 U/ml; Gibco), streptomycin (100 μg/ml; Gibco), 
and 5-bromo-2-deoxyuridine (BrdU; 100 μmol/L; Sigma). After 30 h, the medium was changed to ACCT 
medium, serum-free DMEM supplemented with 2 g/l albumin, 2 mM L-carnitine, 5 mM creatine and 
5 mM taurine (all from sigma) and experiments were performed on the following day. Adult rat CMs 
were isolated as previously described by Asrih et al. (Asrih et al., 2011) and plated onto laminin-coated 
culture dishes in ACCT medium. 
 
Neonatal heart dissection and protein isolation 
1- to 2-days-old rats were injected i.p. with Nrg1β (PeproTech, 50 μg/kg body weight), insulin (1 U/kg 
body weight) or saline. After 30 min, the animals were sacrificed by decapitation, the heart was 
isolated and put immediately into ice-cooled phosphate-buffered saline. After washing, the atria were 
removed and the ventricles frozen in liquid nitrogen. The tissues were grinded with a Polytron 
homogenizer in RIPA buffer (50 mM Tris·HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.25% Na 
deoxycholate, 0.1% SDS, 5 mM EDTA, and 0.5% phosphatase inhibitor cocktail 2 and 3, 1% protease 
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inhibitor cocktail, 10 mM Na pyrophosphate, 10 mM glycerophosphate from Sigma) and proteins were 
analyzed by Western blot. 
 
Protein extraction and Western blot analysis 
Proteins were extracted with RIPA buffer (50 mM Tris·HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 
0.25% Na deoxycholate, 0.1% SDS, 5 mM EDTA, and 0.5% phosphatase inhibitor cocktail 2 and 3, 1% 
protease inhibitor cocktail from Sigma), separated by SDS-PAGE and transferred to a PVDF membrane 
(Amersham-GE Healthcare). After antibody incubation, the signal was revealed with SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Scientific) and the ChemiDoc MP System (Bio-Rad). Blots 
were quantified with Image Lab (Bio-Rad) and ImageJ (National Institutes of Health). 
 
Glucose uptake assay 
NRVMs were treated with inhibitors for 30 min, followed by 30 min of stimulation by growth factors 
and another 30 min in the presence of deoxy-D-glucose, 2-[1,2-3H(N)] (Perkin-Elmer) and D-glucose (1 
μCi/ml and 100 μM, respectively) in Krebs-Ringer bicarbonate buffer (115 mM NaCl, 4.7 mM KCl, 2.5 
mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 24 mM NaHCO3, 10 mM HEPES, pH 7.4, and 0.1% BSA). 
Afterwards, the cells were washed with ice-cold PBS and lysed in 0.2 M NaOH. One part of the lysate 
was mixed with scintillation liquid (Perkin Elmer) to measure 3H in a β-counter. With the other part, a 
micro BCA protein assay (Thermo Scientific) was performed for normalization of the counts/min. 
Glucose uptake in adult rat CM was measured as previously described by Montessuit et al. (Montessuit 
et al., 2008). 
 
Seahorse assay 
Freshly isolated NRVMs were seeded in a laminin (10 μg/ml) coated 24-well Seahorse plate (60’000 
cells/well). After overnight incubation in ACCT medium, the procedure was done according to the 
manufacturer’s protocol. The adapted glycolytic stress test Seahorse XF24 protocol consisted of 11 
min calibration/equilibration, injection of the stimuli/drugs, followed by 4 min of mixing, 2 min waiting 
and 2 min measuring. The extracellular acidification rate (ECAR) was measured 4 times at base line 
and 3 times after each injection. The rate of glycolysis was determined by subtracting the basal ECAR 
value before glucose injection from the maximal ECAR value after glucose injection. 
 
Immunofluorescence 
Transfected NRVMs were seeded on 13 mm glass cover slips coated with laminin. The cells were 
washed with ice-cold PBS and fixed for 1 h at 4 °C with PBS + 4% formaldehyde (Polyscience). After 
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blocking with PBS + 3% bovine serum albumin for 1 h at RT, the first antibodies were incubated over 
night at 4°C. The samples were washed with PBS and incubated for 1 h at RT with a fluorescent 
secondary antibody and DAPI (1 μg/ml). The samples were washed again and mounted with mounting 
medium (3 mM polyvinyl alcohol 4-88, 33% glycerol, 133.3 mM Tris-HCl pH 8.5 and 2.5% 
diazabicyclooctane) onto a glass slide. The pictures were taken with an Olympus BX63 microscope and 
quantification was done blinded using ImageJ. 
 
Gene expression analysis 
RNA was extracted form NRVMs with Tri Reagent (Sigma) and treated with DNAse I (Ambion). cDNA 
was prepared using the high capacity DNA reverse transcription kit (Applied Biosystems). The product 
was amplified on a 7500 Fast Real-Time PCR system (Applied Biosystems), with GoTaq qPCR Master 
Mix (Promega) and 300 nM for forward and reverse primers in a total volume of 20 μl. Following 
primers were used: rat GLUT1 (5’-ATC AAC GCC CCC CAG AA-3' / 5'-AAT CAT GCC CCC GAC AGA-3'), rat 
GLUT4 (5'-CCC CCG ATA CCT CTA CAT-3' / 5'-GCA TCA GAC ACA TCA GCC CAG-3') and rat GAPDH (5'-
GAT GGT GAA GGT CGG TGT GAA-3' / 5'-TTG AAC TTG CCG TGG GTA GAG-3'). The mRNA level was 
based on the critical threshold (Ct) value. 
 
Reagents 
Neuregulin1β was from R&D Systems (377-HB) for in vitro or PeproTech (100-03) for in vivo 
applications, Insulin and Oligomycin was from Sigma, MG132 was from Calbiochem and IGF-I was from 
Genentech. The antibodies against Akt-pSer473, Akt-pThr308, Akt2, AMPK-pThr172, AMPK, AS160-
pThr642, AS160, ErbB3-pTyr1289, ErbB3, Erk1/2-pThr202/Tyr204, Erk1/2, InsR/IGF-IR-pTyr1146/Tyr1131, IRS-
1-pS636/639, P70S6K1-pThr389 and P70S6K1 were from Cell Signaling Technology. The antibodies against 
ErbB2-pTyr1248, ErbB4, GAPDH, IRS-1, c-Myc and Vinculin were from Santa Cruz Biotechnology. The 
antibody against ErbB4-pTyr1284 was from Abcam. The antibody against IRS-1-pTyr612 was from 
MyBioSource. The antibody against IRS-1-pS307 and IRS-2 were from Upstate. The antibody against -
Tubulin was from Sigma. 
 
Statistical analysis 
All results are expressed as means +/- STDEV. One-way or two-way ANOVA analysis was followed by 





The ErbB2/ErbB4 heterodimer mediates Nrg1β-induced glucose uptake 
We recently reported that Nrg1β enhances glucose uptake in NRVMs via ErbB2/ErbB4 
(Pentassuglia et al., 2016). For a long time, ErbB3 was considered to be expressed only in the 
embryonic heart, while being downregulated after birth (Zhao et al., 1998). However, using 
qRT-PCR and ErbB3-specific antibodies, Camprecios et al. demonstrated that ErbB3 may also 
be expressed in neonatal and adult CMs (Camprecios et al., 2011). We therefore tested 
whether ErbB3 is implicated in the Nrg1β-induced glucose uptake in our NRVM model. 
Knockdown of ErbB3 with siRNA had no effect on Nrg1β-induced glucose uptake, whereas 
reduced ErbB4 levels fully blocked it (Fig. 1A). The efficient knockdown of ErbB3 and ErbB4 
was confirmed by Western blot analysis (Fig. 1B). Like for ErbB4, ErbB2 knockdown also 
blunted the effect of Nrg1β as previously published by our group (Pentassuglia et al., 2016). 
These data demonstrate that ErbB3 is not responsible for the glucose uptake response and 
confirms that ErbB2/ErbB4 heterodimers are implicated. 
 
Nrg1β and insulin have no additive effect on glucose uptake 
We previously demonstrated that Nrg1β induces glucose uptake in NRVMs with similar 
potency as insulin (Pentassuglia et al., 2016). We performed a combined dose-response of 
Nrg1β and insulin to investigate whether the two stimuli have an additive effect. In earlier 
dose-response experiments we established that 10 ng/mL of Nrg1β leads to maximal ErbB 
signaling activation (Pentassuglia et al., 2016). Fig. 2A shows that receptor-saturating 
concentrations of Nrg1β cause a 2-fold increase in glucose uptake. The addition of increasing 
doses of insulin to Nrg1β did not cause any further elevation in glucose uptake. Western blot 
analysis revealed that the two factors had no additive effect on AS160 phosphorylation, 
matching the glucose uptake result, despite their strong additive effect on Akt 
phosphorylation (Fig. 2B). Since insulin is known to increase glycolysis in the heart (Lawson 
and Uyeda, 1987), we next investigated the effect of Nrg1β on glycolysis in comparison to 
insulin. Indeed, Seahorse analysis indicated that elevated glucose uptake was associated with 
increases in glycolysis for both factors (Fig. 2C and D). 
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Nrg1β and insulin have distinct effects on IRS-1 phosphorylation 
It is well-known that IRS mediates insulin- and IGF-induced signaling and in breast cancer cells, 
ErbB1 and ErbB3 were shown to interact with IRS-1 (Knowlden et al., 2011; Knowlden et al., 
2008), and ErbB2 may also interact with IRS (Jones et al., 2006). To evaluate if IRS-1 is 
implicated in the PI3K activation observed in our model, we stimulated NRVMs with insulin 
or Nrg1β for 1, 15, 60 and 120 min and analyzed the protein extracts by Western blotting. Fig. 
3A shows that both stimuli induce phosphorylation of IRS-1 at several sites. Insulin causes a 
rapid transient phosphorylation of Tyr612 with a maximum reached already after 1 min, 
whereas Nrg1β has no effect on that site (Fig. 3A). At later time points, both insulin and Nrg1β 
phosphorylate IRS-1 at Ser636/639 and Ser307. Notably, the effect of Nrg1β on these sites is 
stronger than that of insulin. In addition, for both hormones a band shift of total IRS-1 is visible 
on the Western blots, which is very likely due to its increased phosphorylation status. Since 
IRS-2 is known to play a major role in mediating peripheral glucose uptake (Kaburagi et al., 
1999), we also analyzed total IRS-2. Similar to IRS-1, the IRS-2 band was shifted upwards for 
both insulin and Nrg1β. Thus, while both stimuli induce band shifts of IRS-1/2 and cause IRS-
1 phosphorylation at Ser636/639 and Ser307, only insulin induces IRS-1 phosphorylation at Tyr612. 
Increased phosphorylation of these Ser sites correlates with proteasomal degradation and 
disruption of the InsR-IRS-1 interaction, and are believed to serve as negative feedback loop 
after insulin stimulation (Copps and White, 2012; Rui et al., 2001). In our cells, insulin lowered 
total IRS-1 and IRS-2 at 24 h, and these effects were blocked by the proteasomal inhibitor 
MG132 (Fig. 3B). On the other hand, despite causing strong phosphorylation at the same 
serine sites, Nrg1β did not cause any degradation of IRS. We tested whether increased IRS-1 
Ser phosphorylation changes the response to insulin. After 24 h of pre-incubation with insulin 
or Nrg1β, cells were re-stimulated with insulin for 30 min and glucose uptake was evaluated 
30 min later. Supplementary Fig. 1 shows that both insulin- and Nrg-pre-incubation enhanced 
the insulin-stimulated glucose uptake, indicating that the different phosphorylation state and 
protein levels of IRS1/2 did not modify the response to insulin.  
 
Nrg1β triggers GLUT4 translocation 
Phosphorylation of AS160 is implicated in GLUT4 shuttling to the cell membrane (Jaldin-
Fincati et al., 2017; Leto and Saltiel, 2012). Nrg1β increased AS160-pThr642 and we therefore 
investigated whether Nrg1β induces GLUT4 translocation. To this end, NRVMs were 
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transfected with a plasmid expressing GLUT4-mCherry with a c-Myc tag located on the 
extracellular side (Lim et al., 2015). This allowed us to detect intracellular GLUT4 vesicles and 
identify translocated GLUT4 at the sarcolemma of non-permeabilized cells with an antibody 
specific for the c-Myc tag. Immunofluorescence with specific antibodies to sarcomeric actinin 
confirmed that the majority of GLUT4-positive cells are indeed NRVMs (Fig. 4A). Fig. 4B shows 
representative pictures of c-Myc-positive cells treated with insulin and Nrg1β, respectively. 
Quantification revealed that both stimuli significantly induced GLUT4 translocation to the 
sarcolemma (Fig. 4C). 
To further investigate the role of the glucose transporters, we knocked down GLUT1 and 
GLUT4 (Fig. 4D and E). Knockdown of either GLUT1 or GLUT4 significantly reduced basal and 
insulin-stimulated as well as Nrg1β-stimulated glucose uptake. Taken together, the 
microscopy data indicates that GLUT4 translocation to the sarcolemma is involved in the 
Nrg1β-stimulated glucose uptake, while the knockdown data indicate that both GLUT1 and 
GLUT4 contributes to both basal and stimulated glucose uptake. 
 
Nrg1β causes phosphorylation of cardiac Akt, AS160 and Erk1/2 in vivo 
In our NRVM model, Nrg1β stimulated Akt, AS160 and Erk1/2 phosphorylation. To check 
whether the same signaling pathways are activated in vivo, we injected 1-2 days old neonatal 
rats with insulin and Nrg1β. Analysis of whole heart protein extracts revealed similar signaling 
events compared to our in vitro model. Fig. 5A shows increased ErbB4 phosphorylation after 
Nrg1β stimulation. In addition, Akt-pThr308 and AS160-pThr642 were higher in the presence of 
insulin and Nrg1β, with insulin showing stronger effects than Nrg1β (Fig. 5B). Consistent with 
its increased phosphorylation, the band of Akt2 was shifted upwards for both stimuli. Finally, 
and again similar to our in vitro findings, Nrg1β induced phosphorylation of Erk1/2 at 
Thr202/Tyr204. 
 
Nrg1β does not increase glucose uptake in cardiomyocytes from adult rats 
Nrg1β is known to be cardioprotective in adult rodent models (Liu et al., 2006). We therefore 
proceeded to investigate its effects on glucose uptake in adult rat CMs. Immediately after 
their isolation, the CMs were stimulated with insulin or Nrg1β and glucose uptake was 
measured (Fig. 6A). Insulin induced a significant increase in glucose uptake, whereas Nrg1β 
had no effect. A dose-response with Nrg1β showed that glucose uptake was not increased 
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even at the highest concentration used, which was 1 μg/ml (Fig. 6B). Signaling analysis 
matched the results of the glucose uptake assay as Nrg1β induced only very small increases 
in Akt and AS160 phosphorylation, whereas insulin had strong effects on both targets (Fig. 
6C). Like in our NRVMs, Erk1/2 phosphorylation was elevated in presence of Nrg1β, 




The fetal heart primarily uses glucose as energy substrate. During the first week after birth 
substrate preference switches from glucose to fatty acids. Under stress conditions, the adult 
heart again increases glucose consumption at the expense of fatty acids to sustain the high 
energy demand needed for continuous contraction (Lopaschuk and Jaswal, 2010). This is 
associated with a changed pattern of gene expression, resembling that of the fetal and 
neonatal heart. Ischemic and hemodynamic stress conditions also trigger the myocardial 
endothelium to release Nrg1, favoring recovery and preserving function of the heart (Hedhli 
et al., 2011). It is currently not known whether these cardioprotective actions are explained 
by regulatory effects of Nrg1 on metabolism. Recently, we demonstrated that Nrg1β 
enhances glucose uptake in NRVMs via PI3K and Akt (Pentassuglia et al., 2016). In the 
present study, we investigated the implicated mechanism in comparison to the well-studied 
insulin-induced glucose uptake. 
Our findings show that Nrg1β induces glucose uptake and increases glycolysis to the same 
extent as insulin and that the two factors have no additive effect in NRVMs. This is in contrast 
to skeletal muscle cells, in which an additive effect was observed (Canto et al., 2004). 
Previously, we concluded that the ErbB2/ErbB4 heterodimer is responsible for the Nrg1β-
stimulated glucose uptake (Pentassuglia et al., 2016). Using siRNA knockdown, we here 
additionally show that ErbB3 is not involved, which strengthens our own earlier finding for 
NRVMs, but differs from that reported in L6E9 skeletal muscle cells (Canto et al., 2004). 
Similar to other tyrosine kinase receptors including InsR/IGF-IR, the ErbB receptors can 
activate the PI3K pathway. Best-known for this activity is ErbB3 (Carraway et al., 1995; Hellyer 
et al., 1995), but in the present study we excluded its role in our cardiomyocyte model. 
Downstream of the InsR/IGF-IR, IRS-1/2 proteins mediate insulin-induced PI3K activation 
 49 
(Peng and He, 2018). By analyzing several phosphorylation sites of IRS-1 over time, we 
showed that only insulin rapidly induces Tyr612 phosphorylation, a site that indicates increased 
activity of IRS-1 (Esposito et al., 2001). On the other hand, at later time points Nrg1β increased 
phosphorylation of IRS-1 on Ser636/639 and Ser307. While insulin also phosphorylated these 
sites, the Nrg-induced phosphorylation was much stronger. Since Nrg1β enhances mTORC1 
activity in NRVMs (Pentassuglia et al., 2016), the elevated IRS-1 serine phosphorylation may 
be secondary to mTOR/S6K1 activation, consistent with the timepoint at which the effect 
occurs. IRS-1 phosphorylation at Ser636/639 may also depend on Erk1/2 (Bouzakri et al., 2003), 
a MAPK strongly phosphorylated by Nrg1β in our model. Phosphorylation of these serine sites 
are thought to cause a negative feedback loop that leads to decreased activity and eventual 
proteasomal degradation of IRS-1 (Copps and White, 2012). Notably, total IRS-1 and IRS-2 
protein levels were decreased after 24 h of insulin, but not after Nrg1β stimulation. The 
insulin-induced decrease was blocked by the proteasomal inhibitor MG132. This shows that 
insulin triggers proteasomal degradation of IRS-1/2 consistent with previous publications 
(Greene et al., 2003), whereas Nrg1β does not cause any IRS degradation, indicating that 
phosphorylation of the Ser sites by itself is not enough to trigger degradation. Whether 
ubiquitination and proteasomal degradation of IRS requires phosphorylation of the activation 
site and/or other sites remains to be investigated. Notably, the different phosphorylated and 
total protein levels of IRS did not modify the responsiveness to insulin in our model. 
Moreover, the lack of a negative feedback loop after Nrg stimulation suggests that IRS-1 and 
-2 are not implicated in mediating Nrg1β signaling. Instead, the ErbB2/4 heterodimer may 
directly activate PI3K, as proposed by Jones et al (Jones et al., 2006). 
Downstream of PI3K and Akt and similar to insulin, Nrg1β causes AS160 phosphorylation, 
suggesting that GLUT4 translocation to the sarcolemma is mediating the increase in glucose 
uptake for both factors. Indeed, our microscopy data revealed that Nrg1β is as potent as 
insulin to induce GLUT4 translocation in NRVMs. Similarly, GLUT4 translocation in response 
to Nrg1 was also observed in L6L9 skeletal muscle cells (Canto et al., 2004). Moreover, our 
knockdown experiments provided support that GLUT4 contributes to Nrg1β-induced glucose 
uptake. The lack of a strong inhibition could be due to remaining GLUT4 protein or by 
compensatory uptake via one or more of the other GLUT transporters such as GLUT1, GLUT3, 
GLUT8, GLUT10, GLUT12 and SGLT1, that recently have been detected in the heart (Aerni-
Flessner et al., 2012; Szablewski, 2017). GLUT1 knockdown reduced basal glucose uptake 
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more than GLUT4, consistent with GLUT1 being mainly responsible for basal glucose uptake 
(Kraegen et al., 1993). 
Collectively, our data demonstrate that Nrg1β induces glucose uptake in NRVMs in vitro by 
activating the ErbB2/ErbB4 heterodimer, which triggers phosphorylation of Akt and AS160, 
leading to GLUT4 translocation (Fig. 7). Similarly, Nrg1β also successfully induced ErbB 
signaling in the hearts of neonatal rats, indicated by increases in ErbB4-pTyr1284, Akt-pThr308, 
AS160-pThr642 and Erk1/2-pThr202/Tyr204. Two out of four Nrg1β-treated hearts show only a 
small increase in ErbB4 phosphorylation, indicating that these animals responded less well to 
Nrg1β. Consistently, these hearts also have lower phosphorylated Akt, AS160 and Erk1/2. Still, 
the Nrg1β-induced increase was significant for Akt, whereas for AS160 the effect almost 
reached statistical significance (P=0.052). The data suggest that cardiac glucose uptake may 
be stimulated by Nrg1β in vivo like in vitro. 
On the other hand, clear differences existed between neonatal and adult CMs. Nrg1β did not 
stimulate glucose uptake in adult CMs and consistently, Akt and AS160 phosphorylation was 
very low compared to NRVMs. At the same time, Nrg1β significantly increased Erk1/2 
phosphorylation, indicating activation of the MAPK pathway and confirming responsiveness 
of the cells to Nrg1β. The difference between NRVMs and adult CMs could be due to different 
expression levels of the ErbB isoforms (Camprecios et al., 2011). In contrast to our data, Cote 
et al. showed that Nrg1β increased glucose uptake in adult rat CMs (Cote et al., 2005). This 
discrepancy could be due to the fact that they used the EGF domain of Nrg1β, whereas we 
used the full extracellular domain. Notably, in their dose response experiment no saturation 
of the glucose response was reached at very high concentrations of the peptide. 
Our data revealed clear differences in the responsiveness to Nrg1β between CMs isolated 
from healthy neonatal and adult rats. Possibly, the activation of the Akt pathway and glucose 
uptake along with Erk1/2 activation in neonatal cells is related to the capacity of young mice 
to regenerate their heart (Polizzotti et al., 2015). On the other hand, it was observed that 
Nrg1β signaling is important in the adult heart under stress conditions. Nrg1 expression is 
increased upon mechanical strain as well as during pregnancy, situations when cardiac 
demand is increased (Lemmens et al., 2011; Lemmens et al., 2006). While depressed 
endothelial Nrg synthesis impairs recovery of cardiac contractile function after an ischemic 
insult (Hedhli et al., 2011), treatment with recombinant human Nrg1 peptide improved 
cardiac function in a rat myocardial ischemia model (Liu et al., 2006). Moreover, ErbB3 gene 
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expression is upregulated after ischemia/reperfusion injury and contributes to the recovery 
of the adult heart (Morano et al., 2017). Treating the ischemic heart with additional Nrg1β 
could lead to increased glucose consumption by the CMs, which would supply the heart with 
the energy needed to continue contracting when oxygen levels are too low to perform 
oxidative phosphorylation. 
Taken together, we could show for the first time that Nrg1β induces GLUT4 translocation in 
NRVMs by a similar mechanism as insulin. It remains to be investigated whether Nrg1β 
activates the same mechanism in the adult heart under stress situations. 
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Figure 1. Nrg1β induces glucose uptake independently of ErbB3 
A: NRVMs were transfected with siRNA specific for ErbB3 and ErbB4. 48 h after transfection, 
NRVMs were stimulated for 30 min with Nrg1β (10 ng/ml) or control vehicle. Glucose uptake 
was assessed by 30 min incubation with 1 μCi/ml [3H]-deoxy-D-glucose. Counts were 
normalized to total protein/well (n = 3). B: siRNA-transfected NRVMs were treated for 30 min 
with Nrg1β (10 ng/ml). Western blot analysis was performed to detect ErbB3 and ErbB4. **P 







Figure 2. Nrg1β has no additive effect on glucose uptake in presence of insulin 
A: NRVMs were stimulated for 30 min with an increasing dose of insulin in presence or 
absence of Nrg1β (20 ng/ml) or control vehicle. Glucose uptake was assessed. B: NRVMs were 
treated like in A and the phosphorylation status of the indicated proteins was detected by 
Western blot analysis. C: Extracellular acidification rate (ECAR) was measured by Seahorse 
XF24. The cells were stimulated with Nrg1β (10 ng/ml) or insulin (2.6 nM) and treated with D-
glucose (10 mM), oligomycin (2 μM) and deoxyglucose (50 mM). D: The rate of glycolysis was 
determined according to the manufacturer’s instructions (D, n = 6). *P < 0.05, **P < 0.01, 






Figure 3. Total IRS-1 is reduced and IRS-1 Y612 is only phosphorylated in presence insulin 
A: NRVMs were stimulated for 1, 15, 60 and 120 min with Nrg1β (10 ng/ml), insulin (2.6 nM) 
or control vehicle. By Western blot analysis, the phosphorylation status of the indicated 
proteins was detected. B: NRVMs were preincubated for 30 min with the proteasomal 
inhibitor MG132 (10 μM) or DMSO, followed by 24 h stimulation with Nrg1β or insulin (B). 
Total IRS proteins were detected by Western blot. Representative experiments shown; n = 3. 







Figure 4. Nrg1β induces GLUT4 translocation 
A: Representative picture of NRVMs that were transfected with pLenti-myc-GLUT4-mCherry 
plasmid (Addgene 64049, red). 72 h after transfection, the cells were immunostained against 
sarcomeric actinin (green) and the nuclei were stained with DAPI (blue). Left picture: all 
colors; right picture: only blue and red. Scale bar: 20 μm. B: Representative pictures of pLenti-
myc-GLUT4-mCherry transfected NRVMs, stimulated with Nrg1β (N, 50 ng/ml), insulin (I, 13 
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nM) or control vehicle (C) and fixed after 30 min. With a c-Myc specific antibody, translocated 
GLUT4 was detected by immunofluorescence on non-permeabilized cells. Scale bar: 50 μm. 
C: Quantification of translocated GLUT4 induced by Nrg1β (n = 3, 583 cells), insulin (n = 3, 620 
cells) or control vehicle (n = 2, 476 cells) stimulation. The percentage of c-Myc-positive cells 
out of all transfected GLUT4-mCherry-positive cells was determined. D: NRVMs were 
transfected with siRNA specific for GLUT1 or GLUT4. 48 h after transfection, NRVMs were 
stimulated for 30 min with Nrg1β (10 ng/ml), insulin (2.6 nM) or control vehicle and glucose 
uptake was assessed. Counts were normalized to total protein/well; n = 3. E: The expression 
mRNA of GLUT1 and GLUT4 of siRNA transfected NRVMs was detected by qRT-PCR. *P < 0.05, 
**P < 0.01, ***P < 0.001 and ****P < 0.0001 GLUT1 or GLUT4 vs. scrambled. Control vehicle 








Figure 5. Neonatal rat hearts show a similar signaling response to Nrg1β like in vitro 
A: 1-day-old neonatal rats (n = 4) were injected i.p. with Nrg1β (50 μ/kg body weight), insulin 
(1 U/kg body weight) or saline. 30 min later, animals were sacrificed and proteins were 
extracted from the whole heart. By Western blot analysis, the phosphorylation status of 
several signaling molecules were assessed. B: Quantification of AS160 and Akt, normalized to 
saline. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 vs. saline. Control saline (S), 







Figure 6. Adult cardiomyocytes differ in their response to Nrg1β stimulation 
A: Adult cardiomyocytes were stimulated with Nrg1β (10 ng/ml) or insulin (1 μM) and glucose 
uptake was assessed. B: Adult cardiomyocytes were stimulated with 10, 100 and 1’000 ng/ml 
of Nrg1β. Insulin (1 μM) served as positive control and glucose uptake was assessed. C: In 
parallel, the phosphorylation status of several signaling proteins was detected by Western 
blot analysis. *P < 0.05, ***P < 0.001 and ****P < 0.0001 vs. control vehicle; n = 3. Control 















Supplementary figure 1. Long-term stimulation with insulin and Nrg1β 
A: After 24 h of stimulation with Nrg1β (10 ng/mL), insulin (2.6 nM) or vehicle (control), 
NRVMs were re-stimulated for 30 min with insulin or vehicle. Glucose uptake (cpm, counts 
per minute) was assessed as for Fig. 1. B: The phosphorylation status of the indicated proteins 
was detected after 24 h of stimulation by Western blot analysis. ***P < 0.001 and ****P < 






3.3. Unpublished projects 
 
The data presented in this chapter were not yet included in any manuscript, although the 
experiments were part of my PhD project. As my preliminary data provides important 
information for other studies of our lab and may lead to additional interesting findings, I 
would like here to highlight and discuss some of them. The aims of the experiments were: 
(1) to analyze whether Nrg1β stimulates signaling pathways that regulate glucose metabolism 
using the STZ mouse model of diabetes. 
(2) to test if Nrg1β can stimulate NRVM proliferation. 
(3) to compare the ErbB receptors and glucose transporter expression in adult and neonatal 
whole hearts and NRVMs. 
 




It was observed that the myocardial endothelium releases Nrg1 during ischemia-reperfusion 
(Kuramochi et al., 2004a) and more recently, ErbB3 was demonstrated to contribute to the 
recovery of the heart after an ischemic insult (Morano et al., 2017). Our in vitro experiments 
with NRVMs showed that Nrg can increase glucose uptake, based on which we hypothesized 
that the cardioprotective effects of Nrg1β may, at least in part, be related to enhanced 
glucose use by CMs. Indeed, it is known that glucose uptake increases acutely during ischemic 
events (Russell et al., 2004). As the effects of Nrg in cardiac ischemia models are already being 
investigated by several other groups (Fang et al., 2010; Galindo et al., 2014; Hill et al., 2013; 
Liu et al., 2006) and the technically difficult ischemia model was not established in our 
laboratory, we decided to explore the use of Nrg1β in a different clinical context, namely that 
of diabetes. 
Nrg may be of therapeutic value in diabetic conditions, as suggested by pre-clinical studies in 
rodent models (Li et al., 2013; Li et al., 2011; Vandekerckhove et al., 2016). Diabetic patients 
are prone to develop diabetic cardiomyopathy, which is characterized by diastolic 
dysfunction. T1DM is associated with decreased insulin and hyperglycemia, whereas T2DM is 
associated with increased levels of fatty acids and inflammatory cytokines, impaired 
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responses to insulin and consequently hyperglycemia and hyperinsulinemia. Together, these 
factors change specific molecular pathways in CMs, leading to impaired cardiac contractility 
and cell death (Bugger and Abel, 2014; Kota et al., 2011). In the diabetic heart, the CMs are 
deprived of glucose and limited to fatty acids as energy source. Recently, it was shown that 
i.p. injection of Nrg1β enhances whole body glucose uptake in mice (Ennequin et al., 2015). 
Based on this study as well as our own finding of Nrg1β-stimulated glucose uptake in neonatal 
cardiomyocytes, our aim was to test whether Nrg1β stimulates cardiac glucose uptake in vivo. 
To this end, we started to establish an STZ mouse model of diabetes in our laboratory. STZ 
destroys primarily the beta cells of the islets of Langerhans and thereby reduces insulin 
secretion and consequently increases blood glucose levels (Ito et al., 2001). As a first step 
towards answering the question whether Nrg enhances glucose uptake and thereby 
contributes to the protection of the adult heart, we analyzed signaling pathway activation in 




Nrg1β and insulin lower blood glucose in STZ mice 
After STZ injection, the STZ animals reduced their body weight compared to non-STZ animals, 
which show a constant increase in body weight over time (Fig. 1A). Three weeks after the last 
STZ injection, blood glucose was measured and revealed elevated blood glucose levels in the 
STZ group (Fig. 1B). At 5 weeks after STZ, the hyperglycemic mice were treated with insulin or 
Nrg1β and blood glucose was measured over time (Fig. 2A). Whereas insulin rapidly reduced 
glucose levels to its lowest values (5.6 mM) within 30 min, Nrg1β started to lower blood 
glucose only after 30 min, reaching similarly low levels (7.9 mM) between 60 and 120 min. 
Thus, the kinetics of the two stimuli are clearly different. When the area under the curve 
(AUC) was analyzed, only the glucose-lowering effect of insulin was significant, whereas that 
of Nrg1β showed a trend (P=0.066) (Fig. 2B). The different kinetics suggests distinct 
mechanisms for the two factors. To test whether Nrg1β induces insulin release and thereby 
increases glucose clearance indirectly, we measured plasma insulin levels 30 min after the 
Nrg1β injection, the time point when Nrg1β started to lower blood glucose. As expected, 
plasma insulin was elevated in the insulin-treated mice, confirming that our ELISA assay 
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worked. Notably, Nrg1β did not influence plasma insulin at 30 min after injection (Fig. 2C), 
the time point at which plasma glucose started to decrease in this group of mice.  
 
Analysis of cardiac signaling molecules 
The mice were sacrificed 11 weeks after the last STZ injection and 30 min after i.p. injection 
with the insulin, Nrg1β or saline as a control. Western blot analysis of total protein extracts 
of the left ventricles demonstrated increased phosphorylation of p70S6K1 at Thr389 and 
Erk1/2 at Thr202/204 after Nrg1β stimulation, but no changes in Akt phosphorylation (Fig. 3A). 
In contrast to Nrg1β, insulin triggered phosphorylation of Akt at Thr308. For Nrg1β, AS160 
phosphorylation was not changed, indicating that the GLUT4 translocation-related signaling 
mechanism that we found to be activated in neonatal cardiomyocytes, is not activated in the 
adult heart of STZ-treated mice. Notably, the effect of insulin on AS160 was also small and 
would require more animals. In non-STZ mice, we could not detect any increase in Akt or 
AS160 phosphorylation after Nrg1β stimulation either (data not shown). 
Since we observed that Nrg1β lowered blood glucose, we decided to study another organ that 
could be responsible for blood glucose clearance. Next to fat and skeletal muscle, the liver is 
implicated in glucose uptake and known to increase glycogen synthesis after insulin 
stimulation (Benito, 2011). Therefore, we investigated glucose-metabolism-related signaling 
in the liver of our STZ mice. Indeed, Nrg1β elevated the phosphorylation level of glycogen 
synthase kinase 3β (GSK3β) at Ser9 (Fig. 3B), suggestive of increased glycogen synthesis (Cross 
et al., 1995). Increased phosphorylation of ErbB3 and InsR/IGF-IR after injection of Nrg1β and 
insulin, respectively, confirmed specific receptor activation. Interestingly, Nrg1β strongly 
increased hepatic phosphorylation of Akt at Thr308 and Ser473 and GSK3β at Ser9, whereas the 
increases induced by insulin were less pronounced. 
Finally, we also analyzed signaling in skeletal muscle, but found no differences on Akt 
phosphorylation after Nrg1β injection (data no shown).  
 
Discussion 
Our main finding in this chapter is that Nrg1β lowers blood glucose in STZ mice like insulin, 
however the blood glucose clearance response after Nrg1β and insulin stimulation shows 
different kinetics. We therefore analyzed the possibility that Nrg1β decreases plasma glucose 
as a secondary effect to enhanced insulin secretion. Our data show that this is not the case. 
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In addition, one could still measure plasma IGF-I, which is primarily produced and released by 
the liver and may also lower blood glucose (Schwander et al., 1983). Perhaps the distinct 
kinetics could be explained by the different receptor distributions in the whole body. The 
insulin receptor and the ErbB receptors are expressed in many organs 
(www.proteinatlas.org). Insulin is known to efficiently trigger glucose uptake in several 
tissues, like adipose tissue, liver and skeletal muscle, whereas Nrg1β was previously shown to 
induce glucose uptake only in skeletal muscle cells (Canto et al., 2004). Consistent with our 
results, Nrg1β was recently reported to lower blood glucose in Zucker diabetic fatty rats, 
mainly affecting the liver (Lopez-Soldado et al., 2016). Similarly, Nrg1 improved glucose 
tolerance by ErbB3 activation in the liver in db/db mice (Ennequin et al., 2015). Another 
important point is the route of administration of the hormones, which was done by i.p. 
injection. It could be worth to try an intravenous injection (i.v.), thereby reaching a higher 
concentration of hormone in the heart. 
In summary, we could not detect an effect of Nrg1β on glucose uptake-related signaling 
events in the heart, but we observed that Nrg1β injections affect mainly the liver of STZ mice. 
In the future, it would be worth to test Nrg1β in a model, in which the heart is more stressed, 
because it is known that the Nrg1 and ErbB receptor expression is upregulated under certain 
stress conditions like hemodynamic overload or pregnancy (Lemmens et al., 2011; Morano et 








Figure 1. Effects of streptozotocin on body weight and blood glucose 
Diabetes was induced by STZ administration. 14-16 weeks old C57BL/6N mice were injected 
i.p. with STZ (50 mg/kg body weight) to for 5 consecutive days. A: Body weight measurement 
at the indicated weeks after STZ injection. B: Blood glucose measurement 3 weeks after STZ 







Figure 2. Effect of Nrg1β in streptozotocin mice 
A: 5 weeks after STZ treatment, the mice were injected with Nrg1β (50 μg/kg body weight, n 
= 7), insulin (1 U/kg body weight, n = 7) or saline (n = 9) and blood glucose was measured after 
15, 30, 60 and 120 min. B: Area under the curve (AUC) of A. C: The mice were sacrificed 11 
weeks after STZ. Measurement of plasma insulin levels 30 min after Nrg1β and insulin 
injection. (n = 3-5). **P < 0.01, ***P < 0.001, ****P < 0.0001 Nrg1β or insulin vs. saline; mean 




        
 
Figure 3. Effect of Nrg1β on cardiac and hepatic signaling in streptozotocin mice 
All mice were sacrificed 11 weeks after STZ. A: Western blot analysis of heart protein extracts 
from STZ mice after 30 min of Nrg1β, insulin and saline injection. Levels of blood glucose after 
sacrifice are indicated. B: Western blot analysis of liver protein extracts from STZ mice after 
30 min of Nrg1β, insulin and saline injection. Levels of blood glucose after sacrifice are 
indicated. Saline (S), Nrg1β (N), insulin (I). 
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3.3.2. Nrg1β and IGF-I induce proliferation of NRVMs - preliminary data 
 
Since Nrg1β has been shown to induce CMs proliferation in vivo and thereby may contribute 
to improve heart function (Polizzotti et al., 2015), we investigated the mitogenic effect of 
Nrg1β in NRVMs. To prove increased proliferation correctly, one should evaluate several 
markers. Therefore, I established the immunostaining of Histone H3-pSer10 (p-HH3), Ki67 and 
Aurora B in NRVMs (Fig. 4). All three targets are well accepted markers to analyze proliferation 
in CMs (Leone et al., 2015). The aim of my experiments was to test if Nrg1β can increase the 
number of proliferating CMs in vitro. To this end, NRVMs were stimulated for 48 h with Nrg1β. 
IGF-I was used as positive control since it was previously shown to increase proliferation in 
NRVMs (Kajstura et al., 1994). Immunofluorescent labeling of the three proliferation markers 
revealed positive cells in our cultures. Ki67 labeling detected the highest numbers of positive 
cells, followed by p-HH3 and finally Aurora B (Fig. 4A-C). To confirm that the positive cells 
were CMs and not fibroblasts or other cardiac cells that are always present in low quantities 
in our primary cultures, we performed double-labeling experiments with antibodies specific 
for sarcomeric actinin and p-HH3 (Fig. 4C). Sarcomeric actinin and p-HH3 were co-located in 
many of the cells, identifying these p-HH3-positive cells as cardiomyocytes. Some p-HH3-
positive cells were also negative for sarcomeric actinin. We therefore next quantified only the 
p-HH3/sarcomeric actinin positive cells (Fig. 4D). First of all, this analysis revealed that IGF-I 
increases the number of p-HH3-positive CMs under the culture conditions that we established 
for our NRVMs. Furthermore, incubation with Nrg1β alone had no effect on proliferation. 
Interestingly however, when NRVMs were co-stimulated with Nrg1β and IGF-I, proliferation 
was significantly higher than after stimulation with IGF-I alone (Fig. 2D). Consistent with our 
results, increased DNA synthesis after a combined treatment with Nrg1 and IGF-I was 
observed (Hertig et al., 1999). These data indicate that Nrg1β contributes to the proliferative 
response in NRVMs, but only in the presence of IGF-I. 
In the future, we want to investigate the mechanism whereby Nrg1β enhances the IGF-I-
induced proliferation and test whether Nrg1β-induced glucose uptake contributes to the 








Figure 4. Analysis of Histone H3-pSer10 (p-HH3) in NRVMs 
A: Representative picture of Ki67 staining. DAPI (blue), sarcomeric actinin (red) and Ki67 
(white). Scale bar: 100 μM. B: Representative picture of Aurora B staining. DAPI (blue), 
sarcomeric actinin (red) and Aurora B (green). Scale bar: 20 μM. C: NRVMs were stimulated 
for 48 h with Nrg1β (10 ng/ml), IGF-I (20 ng/ml) or vehicle. After fixation, immunostaining was 
performed. DAPI (blue), sarcomeric actinin (green) and p-HH3 (red). Two representative 
pictures of control and Nrg1β/IGF-I condition. Scale bar: 50 μM. D: Quantification of p-HH3 
positive NRVMs (n=4, > 1’100 cells/sample counted, mean +/- SEM). *P < 0.05, IGF-I vs. 
Nrg1β/IGF-I; **P < 0.01, Nrg1β vs. Nrg1β/IGF-I. Control vehicle (C), Nrg1β (N), IGF-I (IGF). 
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3.3.3. Comparison of GLUT1/4 and ErbB receptors expression in our models 
 
Since we observed different signaling and glucose uptake responses to Nrg1β stimulation in 
our models, we investigated the level of expression of the ErbB receptors and GLUT1/4. 
To examine the neonatal rat model in more detail, we isolated proteins and RNA from the 
heart of P1, P2, P3, P4, P7 and P8 rats. By Western blot analysis, we detected that during the 
first week after birth, protein expression of ErbB2, ErbB4 and β-myosin heavy chain (β-MHC) 
were downregulated, whereas ErbB3 and GLUT4 were upregulated (Fig. 5A). β-MHC is known 
to be highly expressed in the developing heart and downregulated in the adult ventricle, 
matching our observation (Morkin, 2000). p-HH3, which is widely used as proliferation marker 
(Wang and Higgins, 2013), peaked at P2 and was reduced afterwards. This corresponds with 
literature, which demonstrated high proliferation rates after birth that are reduced within the 
first week of life in rats (de Carvalho et al., 2017). 
Moreover, mRNA analysis by qRT-PCR revealed trends of lower GLUT1 and increased GLUT4 
expression one week after birth (Fig. 5B). The mRNA expression levels of the ErbB receptors 
showed some minor tendencies as well. ErbB2 and ErbB4 were lower after one week, whereas 
ErbB1 and ErbB3 were increased compared to P1. In agreement with the literature, GLUT1, 
ErbB2 and ErbB4 are more expressed at birth and GLUT4 and ErbB3 expression gets 
upregulated after birth (Camprecios et al., 2011; Ma et al., 2016; Wang and Hu, 1991). For 
our cell culture model and the in vivo experiment with neonatal rats, we used P1-P2 old rats. 
These results showed that at this time point, the neonatal heart expresses all ErbB receptors, 
GLUT1 and GLUT4 and has very likely increased numbers of proliferating cells, indicated by 
elevated p-HH3. 
In addition, we compared the mRNA expression of GLUT1, GLUT4 and all ErbB receptors in 
NRVMs, a neonatal heart from a P2 rat and an adult rat heart. Indeed, we could confirm that 
the adult heart has a higher expression of GLUT4 and ErbB3 and a lower expression of ErbB2, 
ErbB4 and GLUT1 (Fig. 6A), again matching the findings from literature (Camprecios et al., 
2011; Wang and Hu, 1991). When comparing the isolated NRVMs with the whole neonatal 
heart tissue, which includes all cardiac cell types and not only CMs, a difference is revealed. 
ErbB2 mRNA is higher in isolated CMs than in whole hearts, indicating that ErbB2 density may 
be higher in CMs than in the other cell types of the heart. Similarly, such a comparison of 
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isolated NRVM with neonatal whole hearts indicates that GLUT1 is enriched in CMs. These 
conclusions remain to be confirmed at the protein level. 
Protein lysates from ARVMs were compared with those from NRVMs. Interestingly, ARVMs 
showed much lower ErbB2, ErbB3 and ErbB4 protein levels than NRVMs, whereas GLUT1 and 
GLUT4 proteins were more abundant in ARVMs (Fig. 6B). Surprisingly, GLUT1 expression was 
higher in ARVMs than in NRVMs. This could be explained by the observation of Montessuit et 
al., which showed that ARVMs upregulate GLUT1 after isolation (Montessuit et al., 2004). 
Another explanation could be that it is an artefact of the antibody that might not properly 
detect GLUT1. Therefore, one should test additional antibodies and also measure the mRNA 
level of GLUT1 in ARVMs. 
To conclude, in our models, we observed several differences of ErbB receptor and glucose 
transporter expression at the mRNA and protein level that might explain unequal 
responsiveness to Nrg1β stimulation. Expression of ErbB3 mRNA is much higher in the adult 
heart, whereas ErbB2 and ErbB4 are lower compared to the neonatal heart. Since we 
identified the ErbB2/4 heterodimer to be responsible to mediate Nrg1β-induced glucose 
uptake in NRVMs, this could be an explanation why the adult heart responded less to Nrg1β 
stimulation. In addition, the protein levels of all ErbB receptors were much lower in ARVMs 
compared to NRVMs, proposing that ARVMs may respond less to Nrg1β, which would match 
with our glucose uptake data from ARVMs. In summary, the different expression levels of 








Figure 5. Analysis of the ErbB receptor and GLUT1/4 expression neonatal rats 
A: The hearts from P1, P2, P3, P4, P7 and P8 rats were harvested and proteins were analyzed 
by Western blot. B: From the same rat hearts, RNA was isolated and the expression of several 







Figure 6. Comparison of the ErbB receptor and GLUT1/4 expression in our models 
A: RNA was isolated from NRVMs, a P2 neonatal rat heart and an adult rat heart. The 
expression of several genes was analyzed and normalized to TATA-binding protein (n=1). B: 
The expression of several proteins from NRVM and ARVM protein lysates were compared by 





Clinical trials in chronic heart failure patients revealed positive effects of Nrg1β on heart 
function, although the exact mechanism is not understood (Gao et al., 2010; Jabbour et al., 
2011a; Lenihan et al., 2016). Related to these beneficial observations of Nrg1β on the stressed 
heart, the aim of my thesis was to investigate molecular mechanisms of Nrg1β in CMs that 
could help to explain the positive outcomes in animal models and clinical trials. As previously 
mentioned, the stressed heart is able to adapt its source of energy to increased glucose 
consumption to have continuous energy supply for contraction. To understand the regulation 
of increased glucose consumption, one important factor that needs to be investigated is 
glucose uptake. Therefore, the question of my thesis was if Nrg1β influences glucose uptake 
in CMs and if so, what is the molecular mechanism. 
 
4.1. Nrg1β/ErbB signaling increases glucose uptake in NRVMs 
 
The role of the ErbB receptors was analyzed by using pharmacological inhibitors and receptor 
type-specific siRNAs. Our results show that the ErbB2/4 heterodimer is required for the 
induction of glucose uptake and protein synthesis by Nrg1β in NRVMs, whereas a role of 
ErbB3 was excluded. Moreover, in the unpublished projects chapter, I analyzed and discussed 
the different levels of ErbB receptor expression in our models, which could explain why the 
NRVMs responded stronger to Nrg1β stimulation than the ARVMs. Furthermore, the distinct 
activation of the PI3K and Erk1/2 pathway by Nrg1β stimulation in NRVMs and the absence 
of PI3K pathway activity in ARVMs needs to be further investigated. 
 
4.2. Analysis of the role of c-Src and FAK in Nrg1β-induced glucose uptake 
 
Downstream of the ErbB receptors, effector signaling molecules were investigated to identify 
a link between the receptors and the activated PI3K signaling pathway. Although ErbB4 was 
shown to have a binding site for the p85 subunit of PI3K (Jones et al., 2006), others claim that 
the heart expresses an isoform of ErbB4 without p85 binding sites (Elenius et al., 1999). 
Therefore, we decided to analyze the effect of Nrg1β on c-Src and FAK, out of which c-Src and 
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FAK have already been linked to ErbB signaling in CMs (Kuramochi et al., 2006). Moreover, 
FAK was observed to interact and increase PI3K activity (Chen and Guan, 1994). We applied 
Dasatinib or PP2 to inhibit c-Src, while FAK was blocked by PF-573228. Both Src inhibitors 
blocked Nrg1β-induced glucose uptake, however not completely, which may indicate 
pathway redundancy. In addition, we performed siRNA-based knockdown experiments to 
reduce c-Src and FAK expression, which revealed only an effect on basal glucose uptake. The 
knockdown of both targets was probably not complete enough to fully block c-Src and FAK 
actions or there is an alternative mechanism that still allowed Nrg1β to induce glucose uptake. 
Furthermore, a time course analysis of c-Src phosphorylation at Tyr215 and FAK at Tyr861 
revealed that Akt was phosphorylated at the same time as FAK, whereas c-Src 
phosphorylation was detected much later. These results point to a contribution of FAK in 
NRVMs glucose uptake, although we do not know the exact mechanism yet. c-Src and FAK 
could serve as scaffolding proteins to attract other signaling molecules or they might promote 
cytoskeleton reorganization, allowing GLUT4 vesicle translocation (Brown and Cooper, 1996; 
Huang et al., 2006). Moreover, reduced levels of FAK protein have been associated with 
insulin resistance in high-fat diet-induced diabetic mice (Bisht et al., 2008). Therefore, Nrg1β 
may be a drug candidate to activate FAK signaling and restore insulin sensitivity in diabetic 
individuals. 
 
4.3. Analysis of the role of IRS in Nrg1β signaling 
 
Next to c-Src and FAK, IRS proteins were investigated in the context of Nrg1β stimulation. 
Previously, IRS-1 and IRS-2 have been shown to play an important role to maintain glucose 
homeostasis, since knockout animals develop mild metabolic disorders and growth 
retardation or T2DM and insulin resistance in peripheral tissues, respectively (Araki et al., 
1994; Withers et al., 1998). Since ErbB3 (Knowlden et al., 2011) and FAK (Lebrun et al., 2000) 
were demonstrated to interact with IRS-1, we tested the role of IRS in Nrg1β signaling in 
NRVMs. Due to the fact that no good commercial phopho-IRS-2 antibodies were available, we 
focused on phospho-IRS-1. Therefore, we analyzed several phosphorylation sites on IRS-1 
after insulin and Nrg1β stimulation in NRVMs. A time course analysis revealed obvious 
differences between Nrg1β- and insulin-induced IRS-1 phosphorylation. We observed that 
only insulin increased IRS-1-Tyr612, a site that indicates activation of IRS-1 (Esposito et al., 
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2001) and this increase in phosphorylation happened very early after stimulation. The other 
two Ser phosphorylation sites (Ser307 and Ser636/639) were increased much later, but in contrast 
to Tyr612, by both stimuli. Both Ser sites have been shown to contribute to a negative feedback 
loop mechanism via mTOR and p70S6K1 (Copps and White, 2012). Analysis of total IRS-1 and 
IRS-2 protein showed that long-term stimulation with insulin induced a reduction of both 
proteins, which was dependent on proteasomal degradation, whereas Nrg1β had no effect. 
This effect of insulin on IRS protein degradation has already been observed previously (Rui et 
al., 2001). Interestingly, Nrg1β rather stabilized IRS-1 and IRS-2, indicating no desensitization 
like it is the case for insulin stimulation. Knockdown of IRS-1 and IRS-2 did not show any effect 
on insulin- and Nrg1β-stimulated glucose uptake, likely due to the remaining levels of IRS 
proteins or redundancy by other IRS proteins. In summary, there is a clear impact of Nrg1β 
on IRS-1 and IRS-2 observable in NRVMs, however we did not find a link to Nrg1β-induced 
glucose uptake. 
 
4.4. The PI3K and Akt, but not mTORC2, are implicated in the mechanism 
that mediates Nrg1β-induced glucose uptake 
 
Nrg1β binding to the ErbB receptors is known to activate the PI3K pathway. Activation of PI3K 
could be mediated by a direct interaction with the ErbB3 or ErbB4 receptors or by FAK (Chen 
and Guan, 1994; Schulze et al., 2005). By pharmacological inhibition of several isoforms of 
PI3K, we identified PI3K as the responsible isoform mediating Nrg1β-induced glucose 
uptake. After inhibition of PI3K, Nrg1β stimulation of Akt phosphorylation at Thr308 and 
Ser473 was blocked. Both phosphorylation sites were shown to be needed for full activation 
of Akt (Alessi et al., 1996). Moreover, activation of Akt is crucial since the blockage of Akt with 
Akt inhibitor VIII completely abolished Nrg1β-induced glucose uptake. Taking into account 
that Akt is phosphorylated at Ser473 by mTORC2 (Hresko and Mueckler, 2005; Sarbassov et al., 
2005), the role of mTORC2 in Nrg1β-induced glucose uptake was investigated by comparing 
the effects of the pharmacological inhibitors, Rapamycin and PP242, and siRNAs specific for 
rapamycin-insensitive companion of mTOR (rictor), an essential component of mTORC2 
(Sarbassov et al., 2004). Our results indicated that mTORC2 and Ser473 phosphorylation of Akt 
are not required for AS160 phosphorylation at Thr642 and glucose uptake upon Nrg1β 
stimulation in NRVMs, matching with our previously published data in adult mice 
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(Pentassuglia et al., 2016; Shende et al., 2016). This is in contrast to insulin-induced glucose 
uptake in skeletal muscle and liver, which were demonstrated to depend on mTORC2 
(Hagiwara et al., 2012; Kumar et al., 2008). Moreover, in brown adipose tissue, it was 
observed that mTORC2 contributes to glucose uptake during cold-induced glucose uptake 
(Albert et al., 2016). However, this is not happening in NRVMs stimulated with Nrg1β. 
 
4.5. AS160 and GLUT4 mediate Nrg1β-induced glucose uptake 
 
Downstream of Akt, AS160 is phosphorylated at Thr642 (Geraghty et al., 2007). AS160 is part 
of a well-studied mechanism in vitro and in vivo that leads upon activation to increased GLUT4 
translocation (Chen et al., 2011; Rowland et al., 2011). After Nrg1β stimulation, we observed 
that AS160 showed increased phosphorylation at Thr642, indicating activation of GLUT4 
translocation (Sano et al., 2003). To test whether GLUT4 translocates to the sarcolemma, we 
overexpressed GLUT4 linked to a c-Myc tag on its extracellular part in NRVMs. Our data 
revealed that Nrg1β induces GLUT4 translocation to a similar extent as insulin. However, the 
disadvantage of this approach is the fact that the GLUT4 levels are much higher than under 
physiological conditions since its expression is regulated by the ubiquitin promoter. Next to 
this approach, we performed cell fractionation and immunostaining experiments to detect 
GLUT4 translocation of the endogenous GLUT4 protein. Preliminary data of the cell 
fractionation experiments indicate that endogenous GLUT4 translocates to the sarcolemma 
after Nrg1β stimulation (data not shown), whereas the immunostaining approach failed due 
to technical limitations. To further analyze the contribution of GLUT4 in Nrg1β-induced 
glucose uptake in NRVMs, we knocked down GLUT4 with specific siRNAs. Data from these 
experiments confirmed that GLUT4 contributes to Nrg1β-induced glucose uptake, although 
the increase was not fully blocked. Possibly, other GLUT transporters are contributing or the 
remaining GLUT4 protein is enough to trigger the small increase of glucose uptake, even 
though it was not significant, which was observed after Nrg1β and insulin stimulation. 
 
4.6. Nrg1β increases AS160 phosphorylation in neonatal rat hearts 
 
Since all signaling analysis and GLUT4 translocation studies were performed in NRVMs, we 
next aimed to confirm our findings using two in vivo models. The first model that we applied 
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was the one-day old neonatal rat. The rats were injected i.p. with Nrg1β or insulin and 30 min 
later the animals were sacrificed to harvest the heart for protein analysis by Western blot. 
Our results showed that Nrg1β increased Akt and AS160 phosphorylation, although to a less 
extent as insulin. These findings indicated that Nrg1β likely increases glucose uptake in the 
neonatal heart like in our NRVM model. To reach higher significance, more animals should be 
included into the study. Another factor that could be adapted is the dose of Nrg1β (50 μg/kg 
body weight), which was chosen according to a pilot experiment and previous studies in adult 
animal models (Caillaud et al., 2015; Ennequin et al., 2015). 
 
4.7. Nrg1β lowers blood glucose of STZ mice 
 
In addition to the neonatal rat model, we applied a diabetic mouse model. STZ was used to 
destroy the pancreatic beta cells of the islets of Langerhans to induce a hyperglycemic state. 
After Nrg1β injection, we measured a decrease of blood glucose to the same level as insulin, 
but with different kinetics. Insulin reduced blood glucose much faster than Nrg1β, indicating 
that the response to Nrg1β could be a secondary effect. Therefore, we measured the level of 
plasma insulin in the Nrg1β-treated mice, but we did not find an increase. Protein analysis of 
the heart revealed no effect on Akt or AS160 phosphorylation upon Nrg1β injection, only 
Erk1/2 showed elevated phosphorylation, confirming activation of ErbB signaling. In addition, 
we examined liver proteins and detected increased phosphorylation of the ErbB3 receptor, 
Akt and GSK3β, indicating raised glycogen synthesis. In the meantime, other groups have 
published similar results in mice and rats showing this effect of Nrg1β on the liver (Caillaud et 
al., 2015; Ennequin et al., 2015; Lopez-Soldado et al., 2016). In summary, Nrg1β lowered 
blood glucose in STZ mice, very likely due to the strong effect on liver ErbB3 activation. In the 
STZ model, the diabetic state likely changes the metabolism of the heart (Mansor et al., 2013), 
which could affect the glucose uptake-related response to Nrg1β. In addition, STZ is known 
to have side effects on other organs (Rerup, 1970; Weiss, 1982), which could as well influence 
the data obtained from this model. We injected our mice i.p., which for future studies could 
be reconsidered to change to another administration route. With an intra venous injection 
one could theoretically reach a higher concentration of Nrg1β in the heart and perhaps lower 
variability. To investigate the effect of Nrg1β on glucose uptake in the heart, one should 
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perform experiments in an ex vivo setup. Thereby, the concentration of glucose and Nrg1β in 
the through flow could be exactly defined. 
 
4.8. ARVMs do not increase glucose uptake upon Nrg1β stimulation 
 
Since we could not find an effect of Nrg1β in the adult heart of STZ mice, we measured glucose 
uptake in ARVMs. For these experiments, we collaborated with Dr. Christophe Montessuit 
from the University of Geneva, who performed the experiments. The data obtained revealed 
no effect on glucose uptake and also Western blot analysis did not show increased Akt or 
AS160 phosphorylation after Nrg1β stimulation. A possible explanation could be that these 
cells express lower levels of the ErbB receptors and therefore are less responsive to Nrg1β 
treatment. We did not measure mRNA levels of the ErbB receptors in ARVMs yet, however 
preliminary data from Western blot analysis indicate lower ErbB2, ErbB3 and ErbB4 protein 
levels compared to NRVMs. 
 
4.9. The ErbB2/4 hetero dimer mediates protein synthesis 
 
Next to glucose uptake, we investigated the mechanism whereby Nrg1β increases protein 
synthesis and analyzed if glucose uptake contributes to protein synthesis in NRVMs. About 20 
years ago, it was already observed that rhGGF2 (soluble Nrg1) can increase protein synthesis 
in NRVMs and ARVMs (Baliga et al., 1999; Zhao et al., 1998). Based on receptor 
phosphorylation, the authors suggested that ErbB2 and ErbB4 could mediate the signal and 
in addition, they showed that Erk1/2 and p70S6K1 are involved in rhGGF2-induced protein 
synthesis. By knocking down ErbB2 and ErbB4, we could demonstrate that both receptors 
contribute to Nrg1β-induced protein synthesis as ErbB2/4 heterodimer. In our study, we 
confirmed increased phosphorylation of Erk1/2 and p70S6K1 after Nrg1β stimulation and in 
addition, we observed elevated phosphorylation of 4E-BP1 and mTOR. Furthermore, when 
we compared Nrg1β-induced protein synthesis in presence of Rapamycin or PP242, we 
showed that mTORC1 only partially contributes to Nrg1β-induced protein synthesis. Since 
mTORC1 inhibition resulted only in a partial protein synthesis inhibition, we propose pathway 
redundancy, which could be responsible for the remaining protein synthesis increase 
observed after Nrg1β stimulation. In consideration that Nrg1β activates the Erk1/2, RSK2 
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(p90S6K family) could mediate the downstream signal to trigger protein synthesis by S6 
activation (Zhao et al., 1998). Indeed, when we blocked Erk1/2 with U0126, protein synthesis 
was as well only partially reduced. This indicates that both signaling pathways, mTOR and 
Erk1/2, contribute to Nrg1β-induced protein synthesis (Pentassuglia et al., 2016). Finally, our 
data from experiments with Indinavir show that glucose uptake contributes to overall protein 
synthesis in NRVMs, but not Nrg1β-induced protein synthesis. These results indicate that next 
to GLUT4 one or more additional glucose transporters are involved in insulin- and Nrg1β-
stimulated glucose uptake in NRVMs. 
 
4.10. Nrg1β and IGF-I together stimulate NRVM proliferation 
 
Recently, we started to investigate the effect of Nrg1β on proliferation in NRVMs. Based on 
our data from p-HH3 immunostainings and preliminary data from DNA synthesis assays (data 
not shown), we concluded that Nrg1β by itself did not increase NRVM proliferation. This was 
in contrast to IGF-I, which was used as positive control. Interestingly, when Nrg1β was 
combined with IGF-I, we observed an additive effect on proliferation. This additive effect has 
already been observed previously in a DNA synthesis experiment (Hertig et al., 1999). 
Recently, Missinato et al. published that Nrg1β induces proliferation in NRVMs, which seems 
to be in contrast to our finding (Missinato et al., 2018). Actually, they cultured their cells in 
medium containing 10% FBS and in addition stimulated with Nrg1β. Probably, our condition 
with IGF-I in the medium mimics the 10% FBS, indicating that Nrg1β needs other growth 
factors to induce NRVM proliferation. However, increased p-HH3-Ser10 phosphorylation and 
DNA synthesis is only a hint for NRVM proliferation, since NRVMs can undergo binucleation 
instead of cytokinesis. To have full proof, one would need to check other markers like Aurora 
B and anillin as proposed by Leone et al. (Leone et al., 2015). 
Interestingly, when we analyzed signaling after combined stimulation with Nrg1β and IGF-I, 
like for insulin, we detected an additive effect on Akt phosphorylation (data not shown). Both 
factors are known to activate the PI3K/Akt pathway. Furthermore, in contrast to IGF-I, Nrg1β 
activates the MAPK/Erk1/2 signaling, which could contribute to an increased proliferation 
rate (Hecquet et al., 2002; Kang and Sucov, 2005). Moreover, in pulmonary epithelial cells, 
Nrg1 was shown to activate the janus kinase/signal transducer and activators of transcription 
(JAK/STAT) pathway, which induced proliferation (Liu and Kern, 2002). If the JAK/STAT 
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pathway is as well involved and if Nrg1β-induced glucose uptake contributes to proliferation 
in NRVMs remains to be investigated. In conclusion, the potential of Nrg1β to increase 
proliferation of NRVMs could play an important role in heart regeneration. 
4.11. Nrg1β, a drug candidate 
 
Overall, our findings contribute to a better understanding of Nrg1β signaling in the heart, 
especially in CMs. In recent years, several positive observations of Nrg1β in the heart have 
been published. As already mentioned in the introduction, Nrg1β lowers levels of apoptosis, 
increases hypertrophy, lowers autophagy, lowers contractility and induces higher 
proliferation rates of CMs in vitro (Baliga et al., 1999; Bersell et al., 2009; Fukazawa et al., 
2003; Lemmens et al., 2004; Zhao et al., 1998). In addition, many in vivo studies with cardiac 
disease models demonstrate beneficial effects such as reduced infarct size, reduced 
mitochondrial dysfunction, lowered CMs apoptosis, increased microvasculature, increased 
CMs proliferation, decreased fibrotic remodeling and overall improved cardiac function, 
which was review by Odiete et al. and Rupert and Coulombe (Odiete et al., 2012; Rupert and 
Coulombe, 2015). A situation in which glucose plays an important role is ischemia. As already 
mentioned, during an ischemic event, Nrg1β is released from the cardiac endothelium. 
Moreover, ErbB3 has been demonstrated to be upregulated after ischemia/reperfusion. 
Therefore, Nrg1β could be of interest in situations when the heart lacks the basal supply of 
glucose. Already about 55 years ago, clinicians started to treat myocardial-ischemia with 
glucose-insulin-potassium infusions to increase glycolysis in the heart, which was shown to 
improve recovery (Grossman et al., 2013). Therefore, Nrg1β might have a similar effect on 
glycolysis in the ischemic heart. So far, Nrg1β was observed to activate the PI3K pathway in 
the heart after ischemia/reperfusion injury (Fang et al., 2010), which might activate glycolysis. 
However, once Nrg1β is applied as drug, one needs to be aware of its effect on blood glucose 
levels. However, in regard to blood glucose handling, Huang et al. have shown that there are 
differences between species and observed that human subjects were not affected (Huang et 
al., 2017).  
As follow-up of our in vitro studies, which analyzed the effects of Nrg1β on CMs, our in vivo 
studies will be very relevant since in the heart Nrg1β acts not only on CMs but also on other 
cell types. These other cells could as well influence the structure and function of the heart. 
For example, Kirabo et al. showed that cardiac fibroblasts respond to Nrg1β with enhanced 
 88 
proliferation, increased viability and secretion of pro-reparative factors like angiopoietin-2, 
brain-derived neurotrophic factor and crypto-1 (Kirabo et al., 2017). Interestingly, Nrg1β was 
demonstrated to reduce fibrosis by increasing ErbB4 phosphorylation in macrophages, which 
reduced their inflammatory activity (Vermeulen et al., 2017). Moreover, Nrg1β was shown to 
increase angiogenesis by inducing vascular endothelial growth factor (VEGF) and 
angiopoietin-1 (Ang1) secretion (Gui et al., 2018; Russell et al., 1999). All these observations 
could be possible mechanisms, whereby Nrg1β improves heart function. However, it is still 
surprising that a short period of Nrg1β treatment had long-lasting effects on heart function 
in patient with chronic heart failure (Gao et al., 2010; Lenihan et al., 2016). Unfortunately, 
there could be a potential risk to development cancer when patients are treated with Nrg1β 
(Vermeulen et al., 2016). Although, Ganapathy et al. reported that there was almost no effect 
on somatic, organ or neoplastic growth in mice (Ganapathy et al., 2016), patients that have 
an elevated risk for cancer should be treated with Nrg1β only with caution or one needs to 




5. Conclusions and outlook 
 
The major achievement of my PhD project is the elucidation of the molecular mechanism how 
Nrg1β induces glucose uptake in NRVMs. I demonstrated that the ErbB2/4 heterodimer 
mediates Nrg1β-induced glucose uptake via the activation of the PI3K, Akt, AS160 signaling 
pathway, which leads to GLUT4 translocation. If the observed glucose uptake contributes to 
the recovery of the heart during or after a stress condition remains to be seen and may 
depend on the stress stimulus. 
 
As follow-up project, our laboratory will apply the transverse aortic constriction model to 
investigate the effect of Nrg1β in the hemodynamically stressed mouse heart in vivo. Cardiac 
function will be assessed by echocardiography and the heart will be analyzed by Western blot, 
immunohistochemistry and qRT-PCR. In another project, one could measure glucose uptake 
after Nrg1β stimulation in an ex vivo setup while mimicking ischemia-reperfusion injury. In 
addition, one could further examine whether causal links exist between glucose uptake and 
the observed increases in protein synthesis and proliferation in vitro. In this context, the role 
of Akt, mTOR and Erk1/2 should be analyze in more detail to elucidate their contribution in 
both processes. Moreover, Nrg1β and insulin/IGF-I showed an additive increase of Akt-pThr308 
phosphorylation without affecting glucose uptake levels. This observation could be 
investigated in more detail as well. 
 
In conclusion, our new findings contribute to a better understanding of the molecular 
mechanism of Nrg1β signaling in CMs and might help to improve the treatment of heart 
disease, in which Nrg1β could be applied as promising drug candidate. Although a lot has 
already been examined, we still need to continue research to further investigate the role of 




6. Material and methods 
 
The majority of all chemical ingredients were purchased from SIGMA, except if another 
company is stated. 
 
6.1. Cell culture 
 
All media and supplements for cell culture were bought from GIBCO Life Technologies if 
nothing is indicated. Pentamycin (100 units/ml), streptomycin (100 μg/ml) and 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 25 mM was added to all cell culture 
media. The cells were cultured in a HERAcell 150 incubator at 37°C and 5% CO2. They were 
kept in plastic ware from Sarstedt. The NRVMs cultured in complete or starvation medium 
indicated in the table below. 
 
Complete Medium 
DMEM 1 g/L Glucose, 10% FBS, 25 mM HEPES, 150 μM BrdU  
Starvation Medium 
DMEM 4.5 g/L Glucose, 25 mM HEPES, 150 μM BrdU, ACCT (albumin 2 g/l, L-carnitine 2 
mM, creatine 5 mM and taurine 5 mM) 
 
6.2. Isolation of neonatal rat ventricular myocytes (NRVMs) 
 
1 to 2 days old neonatal rats were sacrificed by decapitation. The hearts were dissected, the 
atria and big arteries were removed, the ventricles were cut into two pieces and pre-digested 
with 0.05% trypsin-EDTA at 4°C overnight. On the next day, the trypsin solution was discarded 
and the ventricle pieces were washed with complete medium. Afterwards, the ventricles 
were further digested in the water bath at 37°C with 0.83 mg/ml collagenase (Worthington) 
dissolved in HBSS (Hank’s balanced salt solution). Every 2 to 5 min, the cell suspension was 
collected, fresh collagenase solution was added and gently agitated at 37°C. The collected cell 
suspension was transferred into pure fetal bovine serum (FBS) at room temperature (RT). This 
was repeated up to 5 times. The collagenase was removed by pelleting the cells for 6 min at 
60 g. The cell pellet was suspended in complete medium. In order to remove the majority of 
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fibroblasts, which adhere much faster to the plastic surface than NRVMs, the cell suspension 
was pre-plated two times for 1h at 37°C. Afterwards, the NRVMs were counted and plated in 
complete medium containing 150 μM bromodeoxyuridine (BrdU), which keeps the number 
of fibroblasts low. For proliferation experiments, no BrdU was added. Most experiments were 
performed two days after plating. The organ isolation procedure was carried out according to 





NRVMs were transfected by nucleofection with AMAXA biosystems Nucleofector II. Before 
plating the cells on day 2, 3x106 cells were transfected with plasmid DNA or siRNA in 100 μl 
of RTNucleoFector solution (AMAXA Lonza) with program G-009. Immediately after 
electroporation, pre-warmed RPMI medium with 10% FBS was added to the cells and 
incubated for 20 min at 37°C. Afterwards, the cells were transferred into a corresponding 
culture ware, coated with 10 μg/ml laminin, and incubated overnight. The next morning, the 
medium was replaced by fresh medium. On day 4, the cells were used for experiment. 
 
6.4. Experimental procedure 
 
One day before the experiment, NRVMs were calmed down overnight by exchanging the 
complete medium with ACCT medium. The following stimuli and inhibitors were used at final 
concentrations as indicated in the tables below. 
 
Stimuli Company Conc. Receptors 
Neuregulin1β1 R&D 10 ng/ml ErbB3 and ErbB4 
Neuregulin1β1 PeproTech 10 ng/ml ErbB3 and ErbB4 
Insulin Sigma 2.61 nM Insulin receptor 




Inhibitors Company Conc. Target 
Akt inhibitor VIII Calbiochem 20 μM Akt 
AS605240 M. P. Wymann 1 μM PI3K 
Byl-719 M. P. Wymann 1 μM PI3K 
Cal101 M. P. Wymann 1 μM PI3K 
Dasatinib LC Laboratories 1 μM c-Src/BCR-ABL 
Lapatinib LC Laboratories 10 μM ErbB2/EGFR 
LY-294002 Calbiochem 10 μM PI3K 
MG132 APExBIO 10 μM Proteasome complex 9 
Oligomycin Calbiochem 2 μM ATP synthase 
PF573228 Calbiochem 10 μM FAK 
PP2 Calbiochem 5 μM FAK 
PP242 Sigma 2 μM mTOR 
Rapamycin Calbiochem 20 ng/ml FK-binding protein 12 
SB203580 Calbiochem 10 μM p38 MAPK 
TGX-221 M. P. Wymann 1 μM PI3K 
U0126 Calbiochem 10 μM MEK1/2 kinase 
 
6.5. Protein extraction 
 
Radioimmunoprecipitation assay (RIPA) lysis buffer, containing 50 mM TRIS-HCl pH 7.4 
(MERK), 150 mM NaCl, 1% NP40, 0.25% deoxycholate, 1% protease inhibitor cocktail, 0.5% 
phosphatase inhibitor cocktail 2 and 3, 5 mM ethylenediaminetetraacetic acid (EDTA) and 
0.1% sodium dodecyl sulfate (SDS) was used for protein extraction. The cells were washed 
twice with ice-cooled phosphate buffered saline (PBS), lysis buffer was added, cells were 
scratched out of the dish, vortexed for 5 s and incubated for 10 min on ice. Afterwards, the 
extract was centrifuged at 16’000 g at 4°C for 10 min. The supernatant was frozen in liquid 
nitrogen and stored at -80°C.  
 
6.6. Protein assay 
 
Micro BCA Protein Assay Kit from Thermo Scientific was used according to the manufacturer’s 




6.7. Western blot 
 
For Western blot polyacrylamide gels were homemade and electrophoresis was performed 
with PowerPac Basic power supply (Bio Rad). The resolving gel consisted of 375 mM TRIS-HCl 
pH 8.8, 8% to 15% acrylamide/bis (Bio Rad), 0.1% SDS, 0.1% ammonium persulfate (Bio Rad) 
and 0.08% TEMED (Bio Rad). The stacking gel consisted of 125 mM TRIS-HCl pH 6.8, 5.1% 
acrylamide/bis, 0.1% SDS, 0.1% ammonium persulfate (APS) and 0.08% 
tetramethylethylendiamin (TEMED). Before adding TEMED, the solution was deaerated. The 
electrophoresis buffer consisted of 25 mM Tris base, 192 mM glycine and 0.1% SDS. The 
transfer buffer consisted of 25 mM Tris base, 192 mM glycine and 5% methanol (MERK). The 
protein extracts were thawed on ice and mixed with SDS sample buffer (Laemmli), containing 
50 mM TRIS-HCl pH 6.8, 2% SDS, 0.016% bromophenol blue, 10% glycerol and 100 mM 
dithiothreitol (DTT). Afterwards, the samples were denatured by heating for 5 min at 95°C 
and loaded onto the gels. Electrophoretic separation was performed for 1.5 h at 120 V and 
proteins were blotted onto a methanol-pretreated polyvinylidenfluorid (PVDF) membrane 
(GE Healthcare) for 2 h at 350 A in ice-cooled transfer buffer. The proteins were stained with 
Ponceau S solution to check the efficiency of the transfer. The membrane was blocked with 
tris buffered saline (TBS, Tris base 250 mM + NaCl 1.5 M) + 0.1% TWEEN-20 + 5% BSA or 5% 
milk. Primary antibodies were diluted in TBS + 0.1% TWEEN-20 + 5% BSA or 5% milk and the 
membrane was incubated on a shaking platform at 4°C overnight. Horse Radish Peroxidase 
(HRP) secondary antibodies were used, when followed by detection with enhanced chemo 
luminescence (ECL), using SuperSignal West Pico or Dura Chemiluminescent Substrate 
(Thermo Scientific). The ECL signal was recorded with ChemiDoc imaging system from BioRad. 
The Secondary antibodies with an infrared signal were detected with Odyssey from LI-COR 
Bioscience. For quantification, the intensity of the bands was measured with Fiji and 




Following first antibodies were applied: 
Target Catalogue nr. Information 
Akt-pSer473 9271S rabbit, 60 kDa, 1:1000, Cell Signaling 
Akt-pThr308 9275 rabbit, 60 kDa, 1:1000, Cell Signaling 
Akt 2 3063 rabbit, 60 kDa, 1:1000, Cell Signaling 
Akt 9272 rabbit, 60 kDa, 1:1000, Cell Signaling 
AS160-pThr642 AB271 rabbit, 160 kDa, 1:500, Cell Signaling 
AS160 2670 rabbit, 160 kDa, 1:1000, Cell Signaling 
4E-BP1 9452 rabbit, 15 – 20 kDa, 1:2000, Cell Signaling 
ErbB2-pTyr1248 sc-12352-R rabbit, 185 kDa, 1:500, Santa Cruz 
ErbB2 sc-284 rabbit, 185 kDa, 1:500, Santa Cruz 
ErbB3-pTyr1289 4791 rabbit, 185 kDa, 1:1’000, Cell Signaling 
ErbB3 12708 rabbit, 185 kDa, 1:500, Cell Signaling 
ErbB4-pTyr1284 ab61059 rabbit, 185 kDa, 1:500, Abcam 
ErbB4 sc-283 rabbit, 185 kDa, 1:500, Santa Cruz 
Erk1/2-pThr202/Tyr204 9101 rabbit, 42/44 kDa, 1:1000, Cell Signaling 
Erk1/2 9102 rabbit, 42/44 kDa, 1:1000, Cell Signaling 
FAK-pTyr397 3283S rabbit, 125 kDa, 1:1000, Cell Signaling 
FAK-pTyr861 ab38458 rabbit, 125 kDa, 1:1000, Abcam 
FAK sc-558 rabbit, 125 kDa, 1:500, Santa Cruz 
GAPDH sc-32233 mouse, 37 kDa, 1:1000, Santa Cruz 
GLUT1 ab40084 mouse, 45/55 kDa, 1:500, Abcam 
GLUT4 ab654 rabbit, 45/55 kDa, 1:500, Abcam 
IRS-1-pSer307 07-247 rabbit, 170 kDa, 1:500, Upstate 
IRS-1-pSer636/639 2388 rabbit, 180 kDa, 1:1000, Cell Signaling 
IRS-1-pTyr612 MBS624304 rabbit, 180 kDa, 1:500, MyBioSource 
IRS-1 sc-559 rabbit, 170 kDa, 1:500, Santa Cruz 
IRS-2 06-506 rabbit, 170-185 kDa, 1:500, Upstate 
IR/IGF-IR-pTyr1131/1146 3021 rabbit, 95 kDa, 1:1000, Cell Signaling 
P70S6K1-pThr389 9205 rabbit, 70 kDa, 1:1000, Cell Signaling 
P70S6K1 9202 rabbit, 70 kDa, 1:1000, Cell Signaling 
c-Src 36D10 rabbit, 60 kDa, 1:2’000, Cell Signaling 
mTOR-pSer2448 2971 rabbit, 289 kDa, 1:1000, Cell Signaling 
mTOR-pSer2481 2974 rabbit, 289 kDa, 1:1000, Cell Signaling 
mTOR 2972 rabbit, 289 kDa, 1:1000, Cell Signaling 
α-Tubulin T-6199 mouse, 50-55 kDa, 1:1000, SIGMA 
ULK-pSer757 6888 rabbit, 140 kDa, 1:1000, Cell Signaling 
ULK1 A-7481 rabbit, 150 kDa, 1:1000, SIGMA 
Vinculin sc-7649 goat, 117 kDa, 1:1’000, Santa Cruz 
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Following secondary antibodies were applied: 
Target Catalogue nr. Information 
α-rabbit IgG 111-035-003 HRP, 1:10’000, Jackson ImmunoResearch 
α-mouse IgG 115-035-003 HRP, 1:10’000, Jackson ImmunoResearch 
α-goat IgG 305-035-003 HRP, 1:10’000, Jackson ImmunoResearch 
α-mouse IgG 926-32210 IR-Dye 800CW, 1:10’000, LI-COR Biosciences 
 
6.8. RNA isolation 
 
RNAse-free materials were used. The cells were washed twice with ice-cooled PBS and TRI 
reagent was added. The cells were scraped out of the dish, transferred into a micro tube and 
vortexed vigorously. Afterwards, the samples were incubated for 10 min at RT and 
centrifuged for 10 min at 16’100 g at 4°C. The supernatant was transferred into a new micro 
tube and chloroform (MERCK) was added. After vortexing, the samples were again 
centrifuged for 15 min at 9’300 g at 4°C. The aqueous phase was transferred into a new micro 
tube and the RNA was precipitated with isopropanol. The precipitate was centrifuged at 
16’100 g at 4°C for 10 min and washed twice with 70% ethanol. The RNA pellet was first dried 
on air and then re-suspended in RNAse-free water. DNAse treatment with Ambion DNA-free 
DNase Treatment & Removal Reagents kit from life technologies was performed according to 
the manufacturer’s instructions. The RNA concentration was measured with NanoDrop 2000. 
 
6.9. Reverse transcription and quantitative real-time polymerase chain 
reaction 
 
With cDNA reverse transcription kit of Applied Biosystems, 1.5 μg of RNA was reverse 
transcribed into the complementary DNA (cDNA) according to the manufacturer’s 
instructions. A thermocycler from Biometra was used. For the quantitative real-time 
polymerase chain reaction reaction (qRT-PCR) a 7500 Fast Real-Time PCR System from 
Applied Biosystems and the GoTaq qPCR master mix from Promega was used according to the 
manufacturer’s instructions. The cDNA was diluted and added to the reaction mix. The 
measurements of all target genes were performed in triplicates and the housekeeping genes 
in duplicates. The following primers were purchased from Microsynth. 
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Gene Forward primer Reverse primer 
ErbB1 5'-ACA GCA AGG CTT CTT CAA CAG C-3' 5'-GTC TTC TTT GAC ACG GCA GCT-3' 
ErbB2 5'-TTC TGG ATG TCC GAG ACC-3' 5'-TCA TCC CCT TGG CAA TCT GA-3' 
ErbB3 5'-CGA GAT GGG CAA CTC TCA GGC-3' 5'-AGG TTA CCC ATG ACC ACC TCA CAC-3' 
ErbB4 5'-CGG GCC ATT CCA CTT TAC C-3' 5'-TGA CTC CGG CTG CAA TCA G-3' 
GAPDH 5’-GAT GGT GAA GGT CGG TGT GAA-3’ 5’-TTG AAC TTG CCG TGG GTA GAG-3’ 
GLUT1 5’-ATC AAC GCC CCC CAG AA-3' 5'-AAT CAT GCC CCC GAC AGA-3' 
GLUT4 5'-CCC CCG ATA CCT CTA CAT-3' 5'-GCA TCA GAC ACA TCA GCC CAG-3' 
Myoglobin 5'-CGC CAC CAA GCA CAA GAT C-3' 5'-TCA GGA CTT GGA TGA TGA CTT CTG-3' 




For immunofluorescence, cells were cultured in P35 dishes. After treatment, the cells were 
washed twice with cold PBS, fixed and permeabilized for 20 min at 4°C with PBS containing 
4% formaldehyde (Polyscience) and 0.1-0.3% Triton-X100. The samples were then blocked 
with PBS + 0.1% TWEEN + 3% BSA for 1 h at RT and incubated with the first antibody over 
night at 4°C. On the next day, the samples were washed 3 times for 5 min with PBS + 0.1% 
TWEEN-20 and incubated for 1 h at RT with a fluorescent secondary antibody and DAPI (1 
μg/ml). The samples were washed again and mounted onto a glass slide. The mounting media 
consisted of 4.3 mM polyvinyl alcohol 4-88, 33% glycerol, 133.3 mM Tris-HCl pH 8.5 and 2.5% 
diazabicyclooctane. 
 
Following first antibodies were used: 
Target Catalogue number Information 
Aurora B A5102 α-rabbit, 1:200, SIGMA 
Histone H3-pSer10 06-570 α-rabbit, 1:200, Upstate 
Ki67 15580 α-rabbit, 1:200, Abcam 
Sarcomeric actinin A2172 α-mouse, 1:200, Sigma-Aldrich 
 
Following secondary antibodies were used: 
Target Catalogue number Information 
α-mouse IgG A11017 Alexa 488, 1:800, Invitrogen 
α-rabbit IgG A21430 Alexa 555, 1:800, Invitrogen 




An inverted microscope (Zeiss Axiovert 40 C) was used for cell counting. For the detection of 
GFP/mCherry-transfected cells or immunofluorescence, a fluorescent microscope (Olympus 
BX63 or Nikon-Ti) was used. For quantification, the large image scanning function of the 
Nikon-Ti was applied and the images were analyzed with Fiji. 
 
6.12. Seahorse assay 
 
Freshly isolated NRVMs were seeded in a laminin (10 μg/ml) coated 24-well Seahorse plate 
(60’000 cells/well). After overnight incubation in ACCT medium, the medium was again 
changed to Seahorse base medium containing 2 mM L-glutamine and put for 1 h in a CO2-free 
incubator. The hydrated sensor cartridge was loaded with stimuli and inhibitors and inserted 
into the Seahorse XF24 for calibration. Afterwards, the cell plate was put into the Seahorse 
XF24 and extra cellular acidification rate (ECAR) and oxygen consumption rate (OCR) was 
measured. The Seahorse XF24 protocol consisted of 11 min calibration/equilibration, 
injection of the stimuli/drugs, followed by 4 min of mixing, 2 min waiting and 2 min 
measuring. ECAR and OCR were measured 4 times at base line and 3 times after each 
injection. 
 
6.13. Diabetic STZ mouse model 
 
After 4 h of fasting, STZ was administered by i.p. injection (50 mg/kg body weight) to 14-15 
weeks old C57BL/6N mice for 5 consecutive days. STZ was freshly dissolved in 20 mM 
sodiumcitrate at pH 4.5 and kept on ice. Blood glucose was measured with Freestyle Papillon 
Vision from Abbott. For experiments, animals were i.p. injected with Nrg1β (50 μg/kg body 
weight) or insulin (1 U or 34.7 μg/kg body weight) diluted in saline. Body weight was recorded 
over time. For sacrifice, animals were anesthetized with isoflurane and blood was collected 
from the right ventricle. The heart and other organs were harvested and processed for 
Western blot analysis and immunohistochemistry. All animal experiments were carried out 
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